Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ NO ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ NO ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES ☐ NO ☒

The number of shares of registrant’s common stock ~~outstanding~~outstanding as of ~~November 1, 2021~~May 2, 2022 was ~~68,135,798~~70,266,761.

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Such forward-looking statements reflect, among other things:

All of these statements are subject to known and unknown important risks, uncertainties and other factors that may cause our actual results, performance or achievements, market trends, or industry results to differ materially from those expressed or implied by such forward-looking statements. Therefore, any statements contained herein that are not statements of historical fact may be forward-looking statements and should be evaluated as such. Without limiting the foregoing, the words “anticipate,” “expect,” “suggest,” “plan,” “believe,” “intend,” “project,” “forecast,” “estimates,” “targets,” “projections,” “should,” “could,” “would,” “may,” “might,” “will,” and the negative thereof and similar words and expressions are intended to identify forward-looking statements. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in “Risk Factors” in Part II, Item 1A of this report and “Risk Factors Summary” and “Risk Factors” in Part I, Item 1A. of our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2020,~~2021, or the ~~2020~~2021 Form 10-K. Unless legally required, we assume no obligation to

update any such forward-looking information to reflect actual results or changes in the factors affecting such forward-looking information.

When we use the terms “Beam,” the “Company,” “we,” “us” or “our” in this Quarterly Report on Form 10-Q, we mean Beam Therapeutics Inc. and its subsidiaries on a consolidated basis, unless the context indicates otherwise.


	September 30, 2021			December 31, 2020			March 31, 2022			December 31, 2021
Assets
Current assets:
Cash and cash equivalents	$	612,023		$	162,171		$	296,821		$	559,994
Marketable securities		321,382			137,500			925,779			405,653
Collaboration receivable								—			300,000
Prepaid expenses and other current assets		8,019			8,650			16,884			7,360
Total current assets		941,424			308,321			1,239,484			1,273,007
Property and equipment, net		71,533			38,513			94,288			84,258
Restricted cash		14,840			14,840			12,746			12,746
Operating lease right-of-use assets		103,169			86,859			105,543			102,718
Long-term investments		24,538			2,577
Other assets		1,051			567			1,341			1,724
Total assets	$	1,156,555		$	451,677		$	1,453,402		$	1,474,453
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	7,282		$	6,314		$	6,266		$	7,474
Accrued expenses and other current liabilities		22,965			18,463			24,062			28,921
Accrued sub-license fees								33,125			38,743
Derivative liabilities		49,600			71,200			28,600			42,200
Current portion of deferred revenue		12,822			24			115,049			86,270
Current portion of lease liability		6,484			4,218			9,359			7,540
Current portion of equipment financing liability		2,238			2,118			2,337			2,287
Total current liabilities		101,391			102,337			218,798			213,435
Long-term lease liability		133,120			96,014			136,034			134,810
Long-term equipment financing liability		3,598			5,294			2,404			3,007
Contingent consideration liabilities		26,960			0			30,915			31,367
Long-term portion of deferred revenue		36,820			394			225,093			262,303
Other liabilities		852			2,077			11,090			2,793
Total liabilities		302,741			206,116			624,334			647,715
Commitments and contingencies (See Note 7, Leases, Note 9, License agreements and Note 10, Collaboration and license agreements)
Stockholders’ equity:
Preferred stock, $0.01 par value; 25,000,000 shares authorized, and 0 shares issued or outstanding at September 30, 2021 and December 31, 2020, respectively		—			—
Common stock, $0.01 par value; 250,000,000 shares authorized, 68,126,713 and 58,446,016 issued, and 67,734,484 and 57,254,178 outstanding at September 30, 2021 and December 31, 2020, respectively		677			573
Preferred stock, $0.01 par value; 25,000,000 shares authorized, and 0 shares issued or outstanding at March 31, 2022 and December 31, 2021, respectively								—			—
Common stock, $0.01 par value; 250,000,000 shares authorized, 69,785,836 and 68,581,251 issued, and 69,753,023 and 68,389,425 outstanding at March 31, 2022 and December 31, 2021, respectively								698			684
Additional paid-in capital		1,556,685			642,633			1,668,567			1,594,378
Accumulated other comprehensive income (loss)		19			(9	)
Accumulated other comprehensive (loss) income								(2,709	)		(50	)
Accumulated deficit		(703,567	)		(397,636	)		(837,488	)		(768,274	)
Total stockholders’ equity		853,814			245,561			829,068			826,738
Total liabilities and stockholders’ equity	$	1,156,555		$	451,677		$	1,453,402		$	1,474,453

The accompanying notes are an integral part of these condensed consolidated financial statements.


	Three Months Ended September 30,						Nine Months Ended September 30,						Three Months Ended March 31,
	2021			2020			2021			2020			2022			2021
License and collaboration revenue	$	763		$	6		$	775		$	18		$	8,432		$	6
Operating expenses:
Research and development		54,623			29,825			290,306			70,728			65,410			190,106
General and administrative		15,774			7,502			39,450			21,251			19,247			10,273
Total operating expenses		70,397			37,327			329,756			91,979			84,657			200,379
Loss from operations		(69,634	)		(37,321	)		(328,981	)		(91,961	)		(76,225	)		(200,373	)
Other income (expense):
Change in fair value of derivative liabilities		35,800			2,700			(8,400	)		(8,700	)		13,600			(1,900	)
Change in fair value of long-term investments		(4,892	)		—			21,960			517
Change in fair value of non-controlling equity investments														(7,685	)		1,039
Change in fair value of contingent consideration liabilities		10,599			—			9,553			—			452			(305	)
Interest and other income (expense), net		9			169			(63	)		1,016			644			(21	)
Total other income (expense)		41,516			2,869			23,050			(7,167	)		7,011			(1,187	)
Net loss	$	(28,118	)	$	(34,452	)	$	(305,931	)	$	(99,128	)	$	(69,214	)	$	(201,560	)
Unrealized gain (loss) on marketable securities		(12	)		(132	)		28			25			(2,659	)		(15	)
Comprehensive loss	$	(28,130	)	$	(34,584	)	$	(305,903	)	$	(99,103	)	$	(71,873	)	$	(201,575	)
Reconciliation of net loss to net loss attributable to common stockholders:
Net loss	$	(28,118	)	$	(34,452	)	$	(305,931	)	$	(99,128	)
Accretion of redeemable convertible preferred stock to redemption value, including dividends on preferred stock		—			—			—			(1,277	)
Net loss attributable to common stockholders	$	(28,118	)	$	(34,452	)	$	(305,931	)	$	(100,405	)
Net loss per common share attributable to common stockholders, basic and diluted	$	(0.42	)	$	(0.69	)	$	(4.86	)	$	(2.31	)
Weighted-average common shares used in net loss per share attributable to common stockholders, basic and diluted		66,377,611			50,087,747			62,960,219			43,438,919
Net loss per common share, basic and diluted													$	(1.01	)	$	(3.35	)
Weighted-average common shares outstanding, basic and diluted														68,703,864			60,210,120

The accompanying notes are an integral part of these condensed consolidated financial statements.

Condensed Consolidated Statements of ~~Redeemable Convertible Preferred Stock and~~ Stockholders’ ~~(Deficit)~~ Equity


	Redeemable Convertible Preferred Stock						Common Stock				Additional Paid-in			Accumulated Other Comprehensive			Accumulated			Total Stockholders’ (Deficit)			Common Stock				Additional Paid-in			Accumulated Other Comprehensive			Accumulated			Total Stockholders’
	Shares			Amount			Shares		Amount		Capital			Income (Loss)			Deficit			Equity			Shares		Amount		Capital			Income (Loss)			Deficit			Equity
Balance at December 31, 2019		130,616,784		$	302,049			7,326,185	$	73	$	1,851		$	16		$	(203,044	)	$	(201,104	)
Accretion of redeemable convertible preferred stock to redemption value		—			1,277			—		—		(1,277	)		—			—			(1,277	)
Conversion of redeemable convertible preferred stock to common stock upon closing of initial public offering		(130,616,784	)		(303,326	)		29,127,523		291		303,035			—			—			303,326
Issuance of common stock from initial public offering, net of issuance costs of $18.7 million		—			—			12,176,471		122		188,201			—			—			188,323
Balance at December 31, 2020																								57,254,178	$	573	$	642,633		$	(9	)	$	(397,636	)	$	245,561
Issuance of common stock from private placement, net of issuance costs of $8.0 million																								2,795,700		28		251,977			—			—			252,005
Issuance of common stock to acquire Guide																								1,087,153		10		120,022			—			—			120,032
Vesting of restricted common stock		—			—			387,866		4		(4	)		—			—			—			398,804		4		(4	)		—			—			—
Stock-based compensation		—			—			—		—		2,792			—			—			2,792			—		—		4,648			—			—			4,648
Exercise of common stock options		—			—			59,305		1		151			—			—			152			199,284		2		1,756			—			—			1,758
Other comprehensive income (loss)		—			—			—		—		—			(360	)		—			(360	)		—		—		—			(15	)		—			(15	)
Net loss		—			—			—		—		—			—			(30,458	)		(30,458	)		—		—		—			—			(201,560	)		(201,560	)
Balance at March 31, 2020		—		$	—			49,077,350	$	491	$	494,749		$	(344	)	$	(233,502	)	$	261,394
Vesting of restricted common stock		—			—			387,870		4		(4	)		—			—			—
Stock-based compensation		—			—			—		—		2,769			—			—			2,769
Exercise of common stock options		—			—			180,517		1		359			—			—			360
Other comprehensive income (loss)		—			—			—		—		—			517			—			517
Net loss		—			—			—		—		—			—			(34,218	)		(34,218	)
Balance at June 30, 2020		—		$	—			49,645,737	$	496	$	497,873		$	173		$	(267,720	)	$	230,822
Vesting of restricted common stock		—			—			387,867		4		(4	)		—			—			—
Issuance of common stock related to license agreement		—			—			175,000		2		262			—			—			264
Stock-based compensation		—			—			—		—		3,012			—			—			3,012
Exercise of common stock options		—			—			230,136		2		555			—			—			557
Other comprehensive income (loss)		—			—			—		—		—			(132	)		—			(132	)
Net loss		—			—			—		—		—			—			(34,452	)		(34,452	)
Balance at September 30, 2020		—		$	—			50,438,740	$	504	$	501,698		$	41		$	(302,172	)	$	200,071
Balance at March 31, 2021																								61,735,119	$	617	$	1,021,032		$	(24	)	$	(599,196	)	$	422,429

Condensed Consolidated Statements of ~~Redeemable Convertible Preferred Stock and~~ Stockholders’ ~~(Deficit)~~ Equity - Continued


	Common Stock				Additional Paid-in			Accumulated Other Comprehensive			Accumulated			Total Stockholders’			Common Stock				Additional Paid-in			Accumulated Other Comprehensive			Accumulated			Total Stockholders’
	Shares		Amount		Capital			Income (Loss)			Deficit			Equity			Shares		Amount		Capital			Income (Loss)			Deficit			Equity
Balance at December 31, 2020		57,254,178	$	573	$	642,633		$	(9	)	$	(397,636	)	$	245,561
Issuance of common stock from private placement, net of issuance costs of $8.0 million		2,795,700		28		251,977			—			—			252,005
Issuance of common stock to acquire Guide		1,087,153		10		120,022			—			—			120,032
Balance at December 31, 2021																		68,389,425	$	684	$	1,594,378		$	(50	)	$	(768,274	)	$	826,738
Purchase of common stock under ESPP																		28,990		—		1,412			—			—			1,412
Issuance of common stock from At-the-Market offering, net of issuance costs of $1.3 million																		874,770		9		53,927			—			—			53,936
Vesting of restricted common stock		398,804		4		(4	)		—			—			—			283,186		3		(3	)		—			—			—
Stock-based compensation		—		—		4,648			—			—			4,648			—		—		18,035			—			—			18,035
Exercise of common stock options		199,284		2		1,756			—			—			1,758			176,652		2		818			—			—			820
Other comprehensive income (loss)		—		—		—			(15	)		—			(15	)		—		—		—			(2,659	)		—			(2,659	)
Net loss		—		—		—			—			(201,560	)		(201,560	)		—		—		—			—			(69,214	)		(69,214	)
Balance at March 31, 2021		61,735,119	$	617	$	1,021,032		$	(24	)	$	(599,196	)	$	422,429
Issuance of common stock from At-the-Market offering, net of issuance costs of $5.5 million		1,761,285	$	18	$	157,767									157,785
Vesting of restricted common stock		200,403		2		(2	)		—			—			—
Issuance of common stock for success payment liability		349,650		4		29,996									30,000
Stock-based compensation		—		—		10,452			—			—			10,452
Exercise of common stock options		406,225		4		4,079			—			—			4,083
Other comprehensive income (loss)		—		—		—			55			—			55
Net loss		—		—		—			—			(76,253	)		(76,253	)
Balance at June 30, 2021		64,452,682	$	645	$	1,223,324		$	31		$	(675,449	)	$	548,551
Issuance of common stock from At-the-Market offering, net of issuance costs of $8.6 million		2,912,557	$	29	$	318,580		$	—		$	—			318,609
Vesting of restricted common stock		200,402		2		(2	)		—			—			—
Issuance of common stock for success payment liability		—		—		—			—			—			—
Stock-based compensation		—		—		12,968			—			—			12,968
Exercise of common stock options		168,843		1		1,815			—			—			1,816
Other comprehensive income (loss)		—		—		—			(12	)		—			(12	)
Net loss		—		—		—			—			(28,118	)		(28,118	)
Balance at September 30, 2021		67,734,484	$	677	$	1,556,685		$	19		$	(703,567	)	$	853,814
Balance at March 31, 2022																		69,753,023	$	698	$	1,668,567		$	(2,709	)	$	(837,488	)	$	829,068

The accompanying notes are an integral part of these condensed consolidated financial statements.


	Nine Months Ended September 30,						Three Months Ended March 31,
	2021			2020			2022			2021
Operating activities
Net loss	$	(305,931	)	$	(99,128	)	$	(69,214	)	$	(201,560	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		4,817			3,463			3,312			1,398
Amortization of investment discount (premiums)		(28	)		49			(390	)		15
In-process research and development charge		154,953			—			—			154,953
Stock-based compensation expense		28,068			8,573			18,035			4,648
Change in operating lease right-of-use assets		6,781			3,065			1,997			2,359
Non-cash research and development license expense, net		—			5,164
Change in fair value of derivative liabilities		8,400			8,700			(13,600	)		1,900
Change in fair value of contingent consideration liabilities		(9,553	)		—			(452	)		305
Change in fair value of non-controlling equity investments		(21,960	)		(517	)		7,685			(1,039	)
Other		63			—			3			63
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		733			(3,667	)		(9,185	)		(2,365	)
Other long-term assets		(197	)		(56	)		—			(185	)
Accounts payable		(1,341	)		(134	)		(1,252	)		(666	)
Accrued expenses and other liabilities		2,818			4,219			(16,533	)		(4,458	)
Operating lease liabilities		15,208			(3,249	)		(1,780	)		6,111
Collaboration receivable								300,000			—
Deferred revenue		49,224			—			(8,432	)		(6	)
Other long-term liabilities		(153	)		2,075			8,296			(51	)
Net cash used in operating activities		(68,098	)		(71,443	)
Net cash provided by (used in) operating activities								218,490			(38,578	)
Investing activities
Purchases of property and equipment		(33,442	)		(8,232	)		(7,259	)		(11,478	)
Purchases of marketable securities		(606,746	)		(167,094	)		(690,390	)		(289,218	)
Maturities of marketable securities		422,920			157,380			160,310			20,450
Net cash acquired from Guide		620			—			—			620
Purchase of long-term investment		—			(750	)
Net cash used in investing activities		(216,648	)		(18,696	)		(537,339	)		(279,626	)
Financing activities
Proceeds from initial public offering, net of underwriting discount		—			192,510
Proceeds from issuance of common shares, net of commissions		737,205			—			54,003			260,000
Proceeds from issuances of stock under ESPP								1,412			—
Payment of equity offering costs		(8,688	)		(1,717	)		(6	)		(7,955	)
Proceeds from equipment financings		—			1,625
Repayment of equipment financings		(1,576	)		(1,158	)		(553	)		(529	)
Proceeds from exercise of stock options		7,657			1,069			820			1,758
Net cash provided by financing activities		734,598			192,329			55,676			253,274

Net change in cash, cash equivalents and restricted cash		449,852			102,190			(263,173	)		(64,930	)
Cash, cash equivalents and restricted cash—beginning of period		177,011			50,553			572,740			177,011
Cash, cash equivalents and restricted cash—end of period	$	626,863		$	152,743		$	309,567		$	112,081

The accompanying notes are an integral part of these condensed consolidated financial statements.

The accompanying notes are an integral part of these condensed consolidated financial statements

1. Nature of the business and basis of presentation

Organization

Beam Therapeutics Inc., which we refer to herein as the “Company” or “Beam,” is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. Beam’s vision is to provide life-long cures to patients suffering from genetic diseases. The Company was incorporated on January 25, 2017 as a Delaware corporation and began operations in July 2017. Its principal offices are in Cambridge, Massachusetts.

~~In February 2021, the Company entered into an Agreement and Plan of Merger, or the Guide Merger Agreement, to acquire Guide Therapeutics, Inc., or Guide. Pursuant to the Guide Merger Agreement,~~ ~~the Company paid Guide’s former stockholders and optionholders upfront consideration in an aggregate amount of $120.0~~ million, excluding customary purchase price adjustments, in shares of its common stock, based upon the volume-weighted average price of the Company’s common stock over the ten-trading day period ending on February 19, 2021.~~In addition, Guide’s former stockholders and optionholders are eligible to receive up to an additional $100.0~~ ~~million in technology milestone payments and $220.0~~ ~~million in product milestone payments, payable in the Company’s common stock.~~

Liquidity and capital resources

Since its inception, the Company has devoted substantially all of its resources to building its base editing platform and advancing development of its portfolio of programs, establishing and protecting its intellectual property, conducting research and development activities, making arrangements to conduct manufacturing activities with contract manufacturing organizations, research and development costs including preclinical studies and IND-enabling studies, organizing and staffing the Company, maintaining its facilities and new facility build-outs, business planning, raising capital and providing general and administrative support for these operations. The Company is also in the process of developing internal manufacturing capabilities. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, technical risks associated with the successful research, development and manufacturing of product candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.

In ~~February 2020, the Company completed its initial public offering, or IPO, in which the Company issued and sold~~ ~~12,176,471~~ ~~shares of its common stock, including~~ ~~1,588,235~~ ~~shares pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $17.00~~ ~~per share, for aggregate gross proceeds of $207.0~~ ~~million. The Company received approximately $188.3~~ million in net proceeds after deducting underwriting discounts and offering expenses payable by the Company. In connection with the IPO, all outstanding shares of the Company’s redeemable convertible preferred stock converted into ~~29,127,523~~ ~~shares of its common stock.~~

~~In October 2020, the Company issued and sold~~ ~~5,750,000~~ ~~shares of its common stock, including~~ ~~750,000~~ ~~shares pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $23.50~~ ~~per share, for aggregate gross proceeds of $135.1~~ ~~million. The Company received approximately $126.6~~ ~~million in net proceeds after deducting underwriting discounts and offering expenses payable by the Company.~~

On January 16, 2021, the Company entered into a Securities Purchase Agreement with certain purchasers, pursuant to which the Company agreed to sell and issue to the purchasers, in a private placement, shares of common stock of the Company. The closing of the private placement occurred on January 21, 2021. The Company issued and sold ~~2,795,700~~ ~~shares of its common stock at a purchase price of $93.00~~ ~~per share for aggregate gross proceeds of $260.0~~ ~~million, before deducting fees to the placement agents and other offering expenses payable by the Company (See Note 11,~~ ~~Preferred and common stock). The Company received approximately $252.0~~ ~~million in net proceeds after deducting fees to the placement agents and offering expenses payable by the Company.~~

In April 2021, the Company entered into an at the market, or ATM, sales agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, pursuant to which the Company was entitled to offer and sell, from time to time at prevailing market prices, shares of the Company’s common stock having aggregate gross proceeds of up to $300.0 million. The Company agreed to pay Jefferies a commission of up to 3.0% of the aggregate gross sale proceeds of any shares sold by Jefferies under the Sales Agreement. ~~As of September 30,~~Between April and July 2021, the Company ~~has~~ sold 2,908,009 shares of its common stock under the Sales Agreement at an average price of $103.16 per share for aggregate gross proceeds of $300.0 million, before deducting commissions and offering expenses payable by the Company.

In July 2021, the Company and Jefferies entered into an amendment to the Sales Agreement to provide for an increase in the aggregate offering amount under the Sales ~~Agreement,~~Agreement, such that as of July 7, 2021, the Company may offer and sell shares of common stock having an aggregate offering price of an additional $500.0 million. As of ~~September 30, 2021,~~March 31, 2022, the Company has sold ~~1,765,833~~2,873,956

additional shares of its common stock under the amended Sales Agreement at an average price of $~~107.88~~92.71 per share for aggregate gross proceeds of $~~190.5~~266.5 million, before deducting commissions and offering expenses payable by the ~~Company, resulting in an aggregate of $490.5~~ ~~million in gross proceeds received under the Sales Agreement as of September 30, 2021.~~Company.

Since its inception, the Company has incurred substantial losses and had an accumulated deficit of $~~703.6~~837.5 million as of ~~September 30, 2021.~~March 31, 2022. The Company expects to generate operating losses and negative operating cash flows for the foreseeable future.

The Company expects that its cash, cash equivalents, and marketable securities as of ~~September 30, 2021~~March 31, 2022 of $~~933.4~~1.2 ~~million~~billion will be sufficient to fund its operations for at least the next 12 months from the date of issuance of these financial statements. The Company will need additional financing to support its continuing operations and pursue its growth strategy. Until such time as the Company can generate significant revenue from product sales, if ever, it expects to finance its operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. The Company may be unable to raise additional funds or enter into such other agreements when needed on favorable terms or at all. The inability to raise capital as and when needed would have a negative impact on the Company’s financial condition and its ability to pursue its business strategy. The Company will need to generate significant revenue to achieve profitability, and it may never do so.

COVID-19-related significant risks and uncertainties

With the ongoing ~~concern~~concerns related to the COVID-19 pandemic, ~~during 2020 and in the first nine months of 2021,~~ the Company has maintained ~~and expanded~~ its business continuity plans to address and mitigate the impact of the COVID-19 pandemic on its business. In March 2020, to protect the health of its employees, and their families and communities, the Company restricted access to its offices to personnel who performed critical activities that must be completed on-site, limited the number of such personnel that could be present at its ~~faciliti~~esfacilities at any one time, and requested that most of its employees work remotely. In May ~~2020,~~2021, as certain states eased restrictions, the Company established new protocols to better allow its full laboratory staff access to the Company’s facilities. These protocols included several shifts working over a seven-day-week protocol. In June 2021, as certain states continued to ease restrictions, the Company started to allow ~~for all of~~ its ~~employees~~entire workforce the ability to work on-site at the Company’s facilities, with fewer restrictions, particularly for vaccinated employees. The Company~~Company~~

expects to continue incurring additional costs to ensure it adheres to the ~~COVID-19~~ guidelines instituted by the Centers for Disease Control and Prevention and to provide a safe working environment to its onsite employees.

The extent to which the COVID-19 pandemic impacts the Company’s business, its corporate development objectives, ~~and its~~ results of operations and financial condition, ~~including~~and the value of and market for its common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration ~~scope and severity~~ of the pandemic, ~~the duration and extent of~~ travel restrictions, ~~and~~quarantines, social distancing ~~in the United States and other countries, business closures~~ and business ~~disruptions,~~closure requirements, and the effectiveness of actions taken ~~in the United States and other countries~~globally to contain and treat the ~~disease, periodic spikes in infection rates, new strains of the virus that cause outbreaks of COVID-19, and the broad availability of effective vaccines.~~disease. Disruptions to the global economy and supply chain, disruption of global healthcare systems, and other significant impacts of the COVID-19 pandemic could have a material adverse effect on the Company’s business, financial condition, results of operations and growth prospects.

While the COVID-19 pandemic did not significantly impact the Company’s business or results of operations during the ~~nine~~three months ended ~~September 30, 2021,~~March 31, 2022, the length and extent of the pandemic, its consequences, and containment efforts will determine the future impact on the Company’s operations and financial condition.

2. Summary of significant accounting policies

The Company’s significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, ~~2020,~~2021, and notes thereto, which are included in the Company’s Annual Report on Form 10-K that was filed with the Securities and Exchange Commission on ~~March 15, 2021,~~February 28, 2022, or the ~~2020~~2021 Form 10-K. Since the date of those financial statements, there have been no material changes to Beam’s significant accounting ~~policies except as noted below.~~policies.

Basis of presentation

The accompanying condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles, or GAAP. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification, or ASC, and Accounting Standards Update, or ASU, of the Financial Accounting Standards Board, or FASB.

Principles of consolidation

The accompanying condensed consolidated financial statements include the results of operations of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.

In September 2021, the Company's wholly-owned subsidiary Blink Therapeutics Inc., or Blink, merged with and into Beam, such that Blink’s separate corporate existence ceased and Beam continued as the surviving corporation.

Use of estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, ~~the determination of the fair value equity instruments and intangible assets acquired in an asset acquisition,~~ and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. ~~The Company evaluates its~~Significant estimates and assumptions ~~on an ongoing basis.~~reflected in these condensed consolidated financial statements include, but are not limited to, incremental borrowing rate used in the calculation of lease liabilities, research and development expenses, stock-based compensation, contingent consideration liabilities, success payments and certain judgements regarding revenue recognition. Actual results could differ from these estimates.

Cash, cash equivalents, and restricted cash

Cash and cash equivalents consist of standard checking accounts, money market accounts, and all highly liquid investments with a remaining maturity of three months or less at the date of purchase. Restricted cash represents collateral provided for letters of credit issued as security deposits in connection with the Company’s leases of its corporate and manufacturing facilities.

The following table reconciles cash, cash equivalents, and restricted cash reported within the Company’s condensed consolidated balance sheets to the total of the amounts shown in the condensed consolidated statements of cash flows (in thousands):


	September 30, 2021		September 30, 2020		March 31, 2022		March 31, 2021
Cash and cash equivalents	$	612,023	$	137,903	$	296,821	$	97,241
Restricted cash		14,840		14,840		12,746		14,840
Total cash, cash equivalents, and restricted cash	$	626,863	$	152,743	$	309,567	$	112,081

~~Asset acquisitions~~

~~In 2018, the Company~~ ~~adoptedASU 2017-01~~, ~~Business Combinations~~, or ASU 2017-01, which clarified the definition of a business. The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs, and the consideration is allocated to the items acquired based on a relative fair value methodology. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost allocated to acquire in-process research and development with no alternative future use is charged to research and development expense at the acquisition date.8

~~At the time of acquisition, the Company determines if a transaction should be accounted for as a business combination or acquisition of assets.~~

3. Property and equipment, net

Property and equipment consist of the following (in thousands):


	September 30, 2021			December 31, 2020			March 31, 2022			December 31, 2021
Leasehold improvements							$	58,041		$	57,760
Lab equipment	$	24,374		$	17,201			35,489			29,905
Leasehold improvements		12,769			12,706
Furniture and fixtures		1,081			1,078			3,699			3,679
Computer equipment		576			547			1,866			1,646
Construction in process		46,255			15,880			14,527			7,349
Total property and equipment		85,055			47,412			113,622			100,339
Less accumulated depreciation		(13,522	)		(8,899	)		(19,334	)		(16,081	)
Property and equipment, net	$	71,533		$	38,513		$	94,288		$	84,258

The following table summarizes depreciation expense incurred (in thousands):

Three Months Ended September 30,

Nine Months Ended September 30,

2021

2020

2021

2020

Depreciation expense

$
1,675

$
1,218

$
4,642

$
3,463


	Three Months Ended March 31,
	2022		2021
Depreciation expense	$	3,262	$	1,398

4. fair value of financial instruments

The Company’s financial instruments that are measured at fair value on a recurring basis consist of cash equivalents, marketable securities, equity securities of Verve Therapeutics, Inc, or Verve, contingent consideration liabilities related to the agreement and plan of merger pursuant to which the Company acquired Guide, or the Guide Merger Agreement, ~~equity securities of Verve Therapeutics, Inc., or Verve,~~ and success payment derivative liabilities pursuant to the license agreement, or the Harvard License Agreement, between President and Fellows of Harvard University, or Harvard, and the Company, and the license agreement, or the Broad License Agreement, between The Broad Institute, Inc., or Broad Institute, and the Company.

The Company also holds an investment in privately issued corporate equity securities, which are accounted for as investments in equity securities. This investment does not have a readily determinable fair value and the Company values the investment based on the cost of the equity securities adjusted for observable market transactions or impairments, if any, and records any changes in value through earnings.

The following ~~table sets~~tables set forth the fair value of the Company’s financial assets and liabilities by level within the fair value hierarchy at ~~September 30, 2021~~March 31, 2022 (in thousands):


	Carrying amount		Fair value		Level 1		Level 2		Level 3		Carrying amount		Fair value		Level 1		Level 2		Level 3
Assets
Cash equivalents:
Money market funds	$	583,524	$	583,524	$	583,524	$	—	$	—	$	152,020	$	152,020	$	152,020	$	—	$	—
Commercial paper		28,499		28,499		—		28,499		—		144,801		144,801		—		144,801		—
Marketable securities:
Commercial paper		317,324		317,324		—		317,324		—		730,967		730,967		—		730,967		—
Corporate notes		4,058		4,058		—		4,058		—		18,125		18,125		—		18,125		—
Equity securities included in other long-term investments:
U.S. Treasury securities												164,205		164,205		—		164,205		—
Equity securities included in marketable securities:
Corporate equity securities		24,438		24,438		—		24,438		—		12,482		12,482		12,482		—		—
Total assets	$	957,843	$	957,843	$	583,524	$	374,319	$	—	$	1,222,600	$	1,222,600	$	164,502	$	1,058,098	$	—

Liabilities
Success payment liability – Harvard	$	24,700	$	24,700	$	—	$	—	$	24,700	$	14,200	$	14,200	$	—	$	—	$	14,200
Success payment liability – Broad Institute		24,900		24,900		—		—		24,900		14,400		14,400		—		—		14,400
Contingent consideration liability – Technology		19,910		19,910	$	—	$	—	$	19,910		24,531		24,531	$	—	$	—	$	24,531
Contingent consideration liability – Product		7,050		7,050		—		—		7,050		6,384		6,384		—		—		6,384
Total liabilities	$	76,560	$	76,560	$	—	$	—	$	76,560	$	59,515	$	59,515	$	—	$	—	$	59,515

The following ~~table sets~~tables set forth the fair value of the Company’s financial assets and liabilities by level within the fair value hierarchy at December 31, ~~2020~~2021 (in thousands):

Carrying
amount

Fair
value

Level 1

Level 2

Level 3

Assets

Cash equivalents:

Money market funds

$
88,259

$
88,259

$
88,259

$
—

$
—

Commercial paper

60,494

60,497

—

60,497

—

Corporate notes

12,314

12,308

—

12,308

—

Marketable securities:

Commercial paper

113,622

113,622

—

113,622

—

Corporate notes

7,836

7,836

—

7,836

—

U.S. Treasury securities

11,009

11,009

—

11,009

—

Government securities

5,033

5,033

—

5,033

—

Total assets

$
298,567

$
298,564

$
88,259

$
210,305

$
—

Liabilities

Success payment liability – Harvard

$
35,500

$
35,500

$
—

$
—

$
35,500

Success payment liability – Broad Institute

35,700

35,700

—

—

35,700

Total liabilities

$
71,200

$
71,200

$
—

$
—

$
71,200


	Carrying amount		Fair value		Level 1		Level 2		Level 3
Assets
Cash equivalents:
Money market funds	$	540,094	$	540,094	$	540,094	$	—	$	—
Commercial paper		13,997		13,997		—		13,997		—
Corporate notes		5,903		5,903		—		5,903		—
Marketable securities:
Commercial paper		368,743		368,743		—		368,743		—
Corporate notes		16,743		16,743		—		16,743		—
Equity securities included in marketable securities
Corporate equity securities		20,167		20,167		20,167		—		—
Total assets	$	965,647	$	965,647	$	560,261	$	405,386	$	—

Liabilities
Success payment liability – Harvard	$	21,000	$	21,000	$	—	$	—	$	21,000
Success payment liability – Broad Institute		21,200		21,200		—		—		21,200
Contingent consideration liability – Technology		24,359	$	24,359		—		—		24,359
Contingent consideration liability – Product		7,008		7,008		—		—		7,008
Total liabilities	$	73,567	$	73,567	$	—	$	—	$	73,567

Cash equivalents – Money market funds included within cash equivalents are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets. Commercial paper and corporate notes are classified within Level 2 of the fair value hierarchy because pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined through the use of models or other valuation methodologies.

Marketable securities ~~and long-term investments~~– Marketable securities, excluding corporate equity securities, are classified within Level 2 of the fair value hierarchy because pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined using models or other valuation methodologies.

~~During the nine months ended September 30, 2021, the~~The Company ~~held~~holds an investment in Verve consisting of shares of Verve’s common ~~and preferred~~ stock. Prior to Verve's initial public offering in June 2021, the Company valued such investment based on the cost of the equity securities adjusted for any observable market transactions. Following ~~the~~Verve's initial public offering, the equity securities have a readily determinable fair value; however, they ~~are~~were subject to transfer ~~restrictions.~~restrictions for 6 months following Verve's initial public offering. As of ~~September 30, 2021~~March 31, 2022, the Company owned 546,970 shares of Verve's common stock ~~the value of~~valued at $12.5 million, which is included in ~~long-term investments~~marketable securities in the condensed consolidated balance sheet. ~~The~~In addition the Company recorded other expense of $7.7 million and other income of $1.0 million for the ~~investment at~~three months ended March 31, 2022, and 2021 respectively, related to the changes in fair value of $~~24.4~~ ~~million as of September 30, 2021, which resulted in the recognition of $4.9~~ ~~million of other expense and $22.0~~ ~~million of other income for the three and nine months ended September 30, 2021, respectively.~~Verve's stock.

Pursuant to ASU No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities, the Company records changes in the fair value of its investments in equity securities to ~~“Other~~other income (expense), ~~net”~~ in the Company’s condensed consolidated statements of operations.

Success payment liabilities – As discussed further in Note 9, License agreements, the Company is required to make payments ~~determined~~to Harvard and Broad Institute based upon the achievement of specified multiples of the initial weighted average value of the Company’s ~~redeemable convertible Series A-1 Preferred Stock and the Company's redeemable convertible Series A-2 Preferred Stock, or collectively the~~ Series A Preferred Stock or, subsequent to the Company’s initial public offering, or IPO, the market value of ~~Beam’s~~the Company's common stock, at specified valuation dates. The Company’s liability for the share-based success payments under the Harvard ~~License Agreement~~ and Broad License ~~Agreement are~~Agreements is carried at fair value. To determine the estimated fair value of the success payment liability, the Company uses a Monte Carlo simulation methodology, which models the future movement of stock prices based on several key variables.

The following variables were incorporated in the calculation of the estimated fair value of the Harvard and Broad Institute success payment liabilities:


	Harvard						Broad Institute						Harvard						Broad Institute
	September 30, 2021			December 31, 2020			September 30, 2021			December 31, 2020			March 31, 2022			December 31, 2021			March 31, 2022			December 31, 2021
Fair value of common stock (per share)	$	87.01		$	81.64		$	87.01		$	81.64		$	57.30		$	79.69		$	57.30		$	79.69
Expected volatility		77	%		74	%		76	%		74	%		80	%		76	%		80	%		76	%
Expected term (years)	0.10-7.75			0.35-8.49			0.10-8.61			0.35-9.36			0.10-7.25			0.10-7.49			0.10-8.11			0.10-8.36

The computation of expected volatility was estimated using available information about the historical volatility of stocks of similar publicly traded companies in addition to the Company's own data for a period matching the expected term assumption. In addition, the Company incorporated the estimated number, timing, and probability of valuation measurement dates in the calculation of the success payment liability.

The following table reconciles the change in the fair value of success payment liabilities based on Level 3 inputs (in thousands):

Nine Months Ended September 30, 2021

Harvard

Broad Institute

Total

Balance at December 31, 2020

$
35,500

$
35,700

$
71,200

Payments

(15,000
)

(15,000
)

(30,000
)
Change in fair value

4,200

4,200

8,400

Balance at September 30, 2021

$
24,700

$
24,900

$
49,600


	Three Months Ended March 31, 2022
	Harvard			Broad Institute			Total
Balance at December 31, 2021	$	21,000		$	21,200		$	42,200
Change in fair value		(6,800	)		(6,800	)		(13,600	)
Balance at March 31, 2022	$	14,200		$	14,400		$	28,600

Contingent consideration liabilities – As discussed further in Note 8, Guide a~~cquisition~~acquisition, under the Guide Merger Agreement, Guide’s former stockholders and optionholders are eligible to receive up to an additional $100.0 million in technology milestone payments and $220.0 million in product milestone payments, payable in the Company’s common stock valued using the volume-weighted average price of the Company’s stock over the ten-day trading period ending two trading days prior to the date on which the applicable milestone is achieved. As these milestones are payable in the Company’s common stock, the milestone payments result in liability classification under ASC 480, Distinguishing Liabilities from Equity. These contingent consideration liabilities are carried at fair value which was estimated by applying a probability-based model, which utilized inputs based on timing of achievement that were unobservable in the market. These contingent consideration liabilities are classified within Level 3 of the fair value hierarchy.

The following table reconciles the change in fair value of the contingent consideration liabilities based on level 3 inputs (in thousands):

Nine Months Ended September 30, 2021

Technology Milestones

Product Milestones

Total

Balance at February 23, 2021 (inception)

$
29,403

$
7,110

$
36,513

Change in fair value

(9,493
)

(60
)

(9,553
)
Balance at September 30, 2021

$
19,910

$
7,050

$
26,960


	Three Months Ended March 31, 2022
	Technology Milestones		Product Milestones			Total
Balance at December 31, 2021	$	24,359	$	7,008		$	31,367
Change in fair value		172		(624	)		(452	)
Balance at March 31, 2022	$	24,531	$	6,384		$	30,915

The following variables were incorporated in the calculation of the estimated fair value of the contingent consideration liabilities:


	Technology Milestones			Product Milestones			Technology Milestones						Product Milestones
	September 30, 2021			September 30, 2021			March 31, 2022			December 31, 2021			March 31, 2022			December 31, 2021
Discount Rate		7.50	%		7.50	%		8.50	%		7.50	%		8.50	%		7.50	%
Probability of Achievement	10-50%			2-15%			10-75%			10-75%			2-15%			2-15%
Projected Year of Achievement	2022			2023-2028			2022-2023			2022-2023			2024-2029			2023-2029

5. Marketable securities

The following table summarizes the Company’s marketable securities held at ~~September 30, 2021~~March 31, 2022 (in thousands):


	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value		Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Commercial paper	$	317,303	$	26	$	(5	)	$	317,324	$	733,068	$	—	$	(2,101	)	$	730,967
Corporate notes		4,060		0		(2	)		4,058		18,249		—		(124	)		18,125
U.S. Treasury securities											164,689		2		(486	)		164,205
Corporate equity securities											12,482		—		—			12,482
Total	$	321,363	$	26	$	(7	)	$	321,382	$	928,488	$	2	$	(2,711	)	$	925,779

The following table summarizes the Company’s marketable securities held at December 31, ~~2020~~2021 (in thousands):


	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value		Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Commercial paper	$	113,628	$	11	$	(17	)	$	113,622	$	368,778	$	32	$	(67	)	$	368,743
Corporate notes		7,839		2		(5	)		7,836		16,758		—		(15	)		16,743
U.S. Treasury securities		11,009		0		—			11,009
Government securities		5,033		0		0			5,033
Corporate equity securities											20,167		—		—			20,167
Total	$	137,509	$	13	$	(22	)	$	137,500	$	405,703	$	32	$	(82	)	$	405,653

The amortized cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity. At ~~September 30, 2021,~~March 31, 2022, the balance in accumulated other comprehensive ~~loss~~(loss) income was comprised solely of activity related to marketable securities. There were 0 realized gains or losses recognized on the sale or maturity of marketable securities for the ~~nine~~three months ended ~~September 30,~~March 31, 2022 and 2021 ~~and 2020~~ and, as a result, the Company did not reclassify any amounts out of accumulated other comprehensive ~~loss~~(loss) income for the same periods.

The Company holds debt securities of companies with high credit quality and has determined that there was no material change in the credit risk of any of its debt securities. The contractual maturity dates of all the investments are less than one year.

6. Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consist of the following (in thousands):


	September 30, 2021		December 31, 2020		March 31, 2022		December 31, 2021
Employee compensation and related benefits	$	5,841	$	7,591	$	6,771	$	11,661
Research costs		4,987		2,423		6,545		3,133
Professional fees		3,733		1,948		3,542		3,330
Process development and manufacturing costs		3,285		2,272		2,299		3,833
Other		5,119		4,229		4,905		6,964
Total	$	22,965	$	18,463	$	24,062	$	28,921

7. Leases

Operating leases

The Company’s operating leases are as follows:

•

A February 2018 lease for 38,203 square feet of office and laboratory space, which commenced in March 2018 and terminates in September 2028. The lease is subject to fixed-rate rent escalations and provided for $6.1 million in tenant improvements and a term extension option, which is not reasonably certain of exercise.

•

An October 2018 lease for laboratory space as amended, which commenced in April 2019 ~~and was amended in~~ ~~March 2020~~ ~~and~~ ~~April 2020. The amended lease commenced in~~ ~~April 2020~~ and terminates in December 2025. The amended lease is subject to fixed-rate rent escalations and ~~provided~~provides an option to extend the lease for 2 additional two-year periods through December 31, 2029, which are not reasonably certain of being exercised. ~~Upon commencement of the~~Through March ~~2020 amendment,~~31, 2022, the Company has recorded ~~an operating lease~~ right-of-use, or ROU ~~asset~~assets and a lease ~~liability~~liabilities of $~~4.2~~14.1 ~~million. Upon commencement of the April 2020 amendment, the Company recorded an operating lease ROU asset~~million and ~~a lease liability of~~ $~~1.8~~14.0 ~~million.~~million related to this lease.



~~Leases in June 2019 and July 2019 for office and laboratory space, both of which commenced in~~ ~~October 2019~~ ~~and terminate in~~ ~~December 2021. The leases are subject to fixed-rate rent escalations.~~

•

An April 2019 lease for office and laboratory space, ~~to be built.~~that was built over the course of 2020 and 2021. Pursuant to the terms of the original lease agreement, the first phase of the lease commenced in October 2020 (rent payments for the first phase ~~beginning~~began in August 2021) and the second phase of the lease commenced in January 2021 (rent payments for the second phase ~~are expected to begin at the earliest~~began in ~~the first half of 2022)~~February 2022). The lease is subject to fixed-rate rent escalations and provides for $23.4 million in tenant improvements and the option to extend the lease for 2 terms of five years each, which are not reasonably certain of exercise. The Company determined that it is the accounting owner of all tenant improvements. ~~Upon executing the lease, the~~The Company ~~made~~maintains a security deposit of $~~11.8~~9.7 million in the form of a letter of credit, which is included in restricted cash as of ~~September 30, 2021~~March 31, 2022 and December 31, ~~2020.~~2021. Upon commencement of the first phase of this lease in October 2020, the Company recorded an operating lease ROU asset of $66.8 million and a lease liability of $68.8 million and upon commencement of the second phase of this lease in January 2021, the Company recorded an operating lease ROU asset of $22.0 million and a corresponding lease liability of $23.0 million. Subsequently, during the second quarter of 2021, the Company amended the rent commencement dates of the first and second phases of this lease. Pursuant to the terms of the amendment, the lease will terminate onin February ~~28,~~ 2034, which is 12 ~~years~~ years from the amended second phase rent commencement date. As a result, the Company recorded an increase in the ROU asset of $0.5 million and ~~an increase in~~ lease liability of $0.5 million.

The following table summarizes operating lease costs and sublease income (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,				Three Months Ended March 31,
	2021		2020		2021		2020		2022			2021
Operating lease costs	$	4,557	$	1,644		13,660		4,946	$	4,386		$	4,558
Variable lease costs		588		249		1,162		786		1,136			210
Short-term lease costs		383		—		761		0		232			—
Sublease income										(331	)		0
Total	$	5,528	$	1,893	$	15,583	$	5,732	$	5,423		$	4,768

The following table summarizes the lease term and discount rate for operating leases:


	September 30, 2021			December 31, 2020			March 31, 2022			December 31, 2021
Weighted-average remaining lease term (years)	11.4			11.5			10.6			11.1
Weighted-average discount rate		7.1	%		7.4	%		7.0	%		7.0	%

The following table summarizes the lease costs for amounts included in the measurement of lease liabilities (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,				Three Months Ended March 31,
	2021		2020		2021		2020		2022		2021
Operating cash flows used for operating leases	$	3,058	$	2,014	$	7,053	$	5,132	$	4,509	$	1,685
Operating lease liabilities arising from obtaining ROU assets		—		—		24,164		5,795		4,822		23,366

At ~~September 30, 2021,~~March 31, 2022, the future minimum lease payments for the Company’s operating leases for each of the next five years ~~ending December 31~~and total thereafter were as follows (in thousands):


Remainder of 2021	$	4,159
2022		16,616
Remainder of 2022				$	13,865
2023		17,262			19,006
2024		17,787			19,586
2025		18,260			20,066
2026					17,143
Thereafter		132,835			115,692
Undiscounted lease payments		206,919			205,358
Less: imputed interest		(67,315	)		(59,965	)
Total operating lease liabilities	$	139,604		$	145,393

In August 2020, the Company entered into a lease agreement with Alexandria Real Estate Equities, Inc., or the Landlord, to build a 100,000 square foot manufacturing facility in Research Triangle Park, North Carolina intended to support a broad range of clinical programs. The lease has a term of 15 ~~years~~ years following the commencement date and provides the Company the option to extendthe lease term for 2 five-year terms. It is subject to fixed rate escalation increases and also provides up to $20.0 million for reimbursement of tenant improvements. As the lease had not commenced as of ~~September 30, 2021,~~March 31, 2022, the Company has not recorded an operating lease ROU asset or lease liability for this lease in the accompanying condensed consolidated balance sheets. The lease payments are subject to adjustment following the determination of the total project costs of the landlord. The initial estimate of the minimum amount of undiscounted lease payments due under this lease is $~~81.1~~69.0 million. The Company anticipates that the facility will be operational in the first quarter of ~~2023.~~2023 at which time it would begin making rent payments. The tabular disclosure of minimum lease payments above does not include payments due under this lease.

In August 2021, the Company executed a lease amendment to its April 2019 lease for office and laboratory space in Cambridge, Massachusetts to occupy additional space. The term of this lease will run concurrent with the term of the April 2019 lease. The initial estimate of the minimum amount of undiscounted lease payments due under this lease is $11.1 million. As the lease had not yet commenced as of ~~September 30, 2021,~~March 31, 2022, the Company has not recorded an operating lease ROU asset or lease liability for this lease in the accompanying condensed consolidated balance ~~sheets and the tabular disclosure of minimum lease payments above does not include the payments under this lease.~~

In October 2021, the Company executed a lease for additional office and laboratory space at an existing facility. The term of this lease will run through December 31, 2025. The Company took access to part of this space in October 2021 and will record an operating lease ROU asset and lease liability during the fourth quarter of 2021. The initial estimate of the minimum amount of undiscounted lease payments due under this segment of the lease is $~~1.9~~ million. As part of this lease, the Company will take access to the remainder of this space in January 2022 and will record an operating lease ROU asset and lease liability during the first quarter of 2022. The initial estimate of the minimum amount of undiscounted lease payments due under this lease is $~~2.6~~ ~~million.~~sheets. The tabular disclosure of minimum lease payments above does not include ~~the~~ payments due under this ~~segment of the~~ lease.

8. Guide acquisition

On February 23, 2021, the Company entered into the Guide Merger Agreement. Under the Guide Merger Agreement, the Company paid Guide’s former stockholders and optionholders upfront consideration in an aggregate amount of $120.0 million, excluding customary purchase price adjustments and closing costs, in shares of the Company’s common stock, based upon the volume-weighted average price of the Company’s stock over the ten trading day period ending on February 19, 2021. Pursuant to the Guide Merger Agreement, ~~Beam~~the Company acquired all of the issued and outstanding shares of Guide. The Company issued a total of 1,087,153 shares of its common stock valued at $120.0 million in connection with the upfront payment to Guide’s former stockholders and optionholders. The Guide transaction resulted in the acquisition of certain know-how and intellectual property assets related to Guide’s proprietary in vivo LNP screening technology and its library of lipids and lipid nanoparticle formulations identified using the screening technology. Management determined that the acquired assets do not meet the definition of a business pursuant to ASC 805, Business Combinations, as substantially all of the fair value of the acquired assets is concentrated into one identifiable asset, the LNP screening technology and associated lipid library. As of the date of closing of the transactions contemplated by the Guide Merger Agreement, or the Guide Merger Agreement Date, the asset acquired had no alternative future use and had not reached a stage of technological feasibility. As a result, all share-based and cash payment obligations have been recorded as research and development expense in the

accompanying condensed consolidated statements of operations and other comprehensive loss in the amount of $155.0 million. The total transaction price was allocated to the assets acquired and liabilities assumed on a relative fair value basis.

In addition, Guide’s former stockholders and optionholders are eligible to receive up to an additional $100.0 million in technology milestone payments and $220.0 million in product milestone payments, payable in the Company’s common stock valued using the volume-weighted average price of the Company’s stock over the ~~ten-day trading~~ten trading-day period ending two trading days prior to the date on which the applicable milestone is received.

The Company determined that all future technology and product milestone payments are classified as contingent consideration liabilities under ASC 480 and therefore the Company recorded a liability for these ~~milestones~~milestone payments as of the Guide Merger Agreement Date at fair value of $36.5 million. These contingent consideration liabilities ~~will be~~are remeasured at fair value each financial reporting period, with the resulting impact reflected in the Company’s condensed consolidated statements of operations and other comprehensive loss, presented within other income (expense).

The transaction price was determined and allocated as follows (in thousands):


Transaction price
Fair value of equity instruments issued	$	120,032
Technology and product contingent consideration liabilities		36,513
Transaction costs		2,531
Total transaction price	$	159,076
Transaction price allocated
In-process research and development	$	154,953
Cash acquired		3,151
Prepaid expenses and other assets		264
Property and equipment		1,835
Assembled workforce		300
Other liabilities assumed		(1,427	)
Total transaction price	$	159,076

9. License agreements

Harvard license agreement

Under the ~~terms of the~~ Harvard License Agreement, Harvard is entitled to receive success payments, in cash or shares of Company stock, determined based upon the achievement of specified multiples of the initial weighted average value of the Company’s Series A Preferred Stock at specified valuation dates. The success payments range from $5.0 million to a maximum of $105.0 million and have valuation multiples that range from 5 times to 40 times the initial weighted average value of the Series A Preferred Stock. Subsequent to the Company’s ~~February 2020~~ IPO, the amount of success payments is based on the market value of ~~Beam’s~~the Company’s common stock.

The Company is required to make success payments to Harvard during a period of time, or the Harvard Success Payment Period, which has been determined to be the later of (1) the ninth anniversary of the Harvard License Agreement or (2) the earlier of (a) the twelfth anniversary of the Harvard License Agreement and (b) the third anniversary of the first date on which a licensed product receives regulatory approval in the United States. During the Harvard Success Payment Period and beginning one year after the Company’s IPO, the Company will perform a calculation of any amounts owed to Harvard on each rolling 90-day ~~period, commencing one year after the Company’s IPO, with the first success payment becoming due in~~ period.~~May 2021~~.

~~The following table summarizes the Company’s success payment liability for Harvard (in thousands):~~

September 30,
2021

December 31,
2020

Harvard success payment liability

$
24,700

$
35,500

~~The following table summarizes the expense resulting from the change in the fair value of the success payment liability for Harvard (in thousands):~~

Three Months Ended September 30,

Nine Months Ended September 30,

2021

2020

2021

2020

Change in fair value of Harvard success payment liability

$
(17,900
)

$
(1,400
)

$
4,200

$
4,300

In May 2021, the first success payment measurement occurred and amounts due to Harvard were calculated to be $15.0 million. The Company elected to make the payment in shares of the Company’s common stock and issued 174,825 shares of the Company’s common stock to settle this liability on June 10, 2021. The Company may owe Harvard success payments of up to an additional $90.0 million. As of March 31, 2022, 0 success payments were due to Harvard.

The following table summarizes the Company’s success payment liability for Harvard (in thousands):


	March 31, 2022		December 31, 2021
Harvard success payment liability	$	14,200	$	21,000

The following table summarizes the expense resulting from the change in the fair value of the success payment liability for Harvard (in thousands):


	Three Months Ended March 31,
	2022			2021
Change in fair value of Harvard success payment liability	$	(6,800	)	$	1,000

The annual maintenance fee under the Harvard License Agreement is recorded as research and development expense. ~~Patent prosecution~~Annual patent costs ~~are recognized~~will be expensed as ~~expense in the period~~ incurred. As of ~~September 30, 2021,~~March 31, 2022, the Company determined that product development and regulatory approval milestones ~~and royalties~~ under the Harvard License Agreement were not probable and, as such, 0 amounts were recognized for the ~~nine~~three months ended ~~September 30, 2021. As of September 30, 2021,~~March 31, 2022. There was 0 ~~success payments were due~~expense recorded for these milestones for the three months ended March 31, 2021. During the three months ended March 31, 2022 the Company incurred $0.5 million of expense related to non-royalty sublicense fees owed to Harvard. As of March 31, 2022, the Company has accrued $33.1 million of non-royalty sublicense fees owed to Harvard.

Broad license agreement

Under ~~the terms of~~ the Broad License Agreement, Broad Institute is entitled to receive success payments, in cash or shares of Company common stock, determined based upon the achievement of specified multiples of the initial weighted average value of the Series A Preferred Stock at specified valuation dates. The success payments range from $5.0 million to a maximum of $105.0 million and have valuation multiples that range from 5 times to 40 times the initial weighted average value of the Series A Preferred Stock. Subsequent to the ~~Company’s February 2020~~Company's IPO, the amount of success payments is based on the market value of ~~Beam’s~~the Company’s common stock.

The Company is required to make success payments to Broad Institute during a period of time, or the Broad Success Payment Period, which has been determined to be the earliest of (1) the twelfth anniversary of the Broad License Agreement or (2) the third anniversary of the first date on which a licensed product receives regulatory approval in the United States. During the Broad Success Payment Period and beginning one year after the Company’s IPO, the Company will perform a calculation of any amounts owed to Broad Institute on each rolling 90-day ~~period, commencing one year after the Company’s IPO, with the first success payment becoming due in~~ period.~~May 2021~~.

~~The following table summarizes the Company’s success payment liability for Broad Institute (in thousands):~~

September 30,
2021

December 31,
2020

Broad Institute success payment liability

$
24,900

$
35,700

~~The following table summarizes the expense resulting from the change in the fair value of the success payment liability for Broad Institute (in thousands):~~

Three Months Ended September 30,

Nine Months Ended September 30,

2021

2020

2021

2020

Change in fair value of Broad Institute success payment liability

$
(17,900
)

$
(1,300
)

$
4,200

$
4,400

In May 2021, the first success payment measurement occurred and amounts due to Broad Institute were calculated to be $15.0 million. The Company elected to make the payment in shares of the Company’s common stock and issued 174,825 shares of the Company’s common stock to settle this liability on June 10, 2021. The Company may owe Broad Institute success payments of up to an additional $90.0 million. As of March 31, 2022, 0 success payments were due to Broad Institute.

The following table summarizes the Company’s success payment liability for Broad Institute (in thousands):


	March 31, 2022		December 31, 2021
Broad Institute success payment liability	$	14,400	$	21,200

The following table summarizes the expense resulting from the change in the fair value of the success payment liability for Broad Institute (in thousands):


	Three Months Ended March 31,
	2022			2021
Change in fair value of Broad Institute success payment liability	$	(6,800	)	$	900

The annual maintenance fee under the Broad License Agreement is recorded as research and development expense. ~~Patent prosecution~~Annual patent costs ~~are recognized~~will be expensed as ~~expense in the period~~ incurred. As of ~~September 30, 2021,~~March 31, 2022, the Company determined that product development and regulatory approval milestones and royalties under the Broad License Agreement were not probable and, as such, 0 amounts were recognized for the ~~nine~~three months ended ~~September 30, 2021. As of September 30, 2021,~~March 31, 2022. There was 0 ~~success payments were due~~expense recorded for these milestones for the three months ended March 31, 2021. The Company paid $6.1 million of non-royalty sublicense fees to Broad ~~Institute.~~Institute during the three months ended March 31, 2022.

Editas license agreement

In May 2018, the Company entered into a license agreement, or the Editas License Agreement, with Editas Medicine, Inc., or Editas. Pursuant to the Editas License Agreement, Editas granted to the Company licenses and options to acquire licenses to certain intellectual property rights owned or controlled by Editas, for specified uses.

The annual maintenance fees under the Editas License Agreement are recorded as research and development expense. Annual patent costs are expensed as incurred. In addition, the Company is required to make certain development, regulatory and commercial milestone payments to Editas upon the achievement of specified milestones. ~~As of September 30, 2021, the~~The Company ~~determined that it owed a regulatory milestone payment to Editas under the License Agreement and recognized~~recorded $0.1 million of expense ~~for~~related to these milestones during the three ~~and nine~~ months ended ~~September 30, 2021.~~

~~Bio Palette license agreement~~

In March 2019, the Company entered into a license agreement, or the Bio Palette License Agreement, with Bio Palette Co., Ltd., or Bio Palette, pursuant to which the Company received an exclusive (even as to Bio Palette), sublicensable license under certain patent rights related to base editing owned or controlled by Bio Palette to exploit products for the treatment of human disease throughout the world, but excluding products in the microbiome field in Asia. In addition, the Company granted Bio Palette an exclusive (even as to the Company) license under certain patent rights related to base editing and gene editing owned or controlled by the Company to

exploit products in the microbiome field in Asia. Each party to the agreement retains non-exclusive rights to develop and manufacture products in the microbiome field worldwide for the sole purpose of exploiting those products in its own territory. Each party agrees to certain coordination obligations in the microbiome field if either party determines not to exploit their rights in such field. Upon the execution of the Bio Palette License Agreement, the Company paid Bio Palette an upfront fee of $~~0.5~~ ~~million and issued to Bio Palette~~ ~~16,725~~ ~~shares of its common stock valued at $0.1~~ ~~million.~~

Unless earlier terminated, the Bio Palette License Agreement will expire on a licensed product-by-licensed product and country-by-country basis upon the expiration of the applicable royalty term for each such licensed product and country.

~~Upon the issuance of a certain Bio Palette patent in the United States in June 2020, the Company made a milestone payment of $2.0~~ ~~million and, in July 2020, issued to Bio Palette~~ ~~175,000~~ ~~shares of its common stock valued at $0.3~~ million. The fair value of the common stock issued to Bio Palette under the Bio Palette License Agreement was measured at the inception of arrangement and expensed when the issuance of shares became probable.31, 2022.

Management concluded that the licenses acquired from each transaction above did not meet the accounting definition of a business as inputs, but no processes or outputs were acquired with the licenses, and the licensed technology had not achieved technological feasibility. As the inputs that were acquired along with the licenses do not constitute a “business,” the transactions have been accounted as asset acquisitions. As of the date of each license agreement, the assets acquired had no alternative future use and the assets had not reached a stage of technological feasibility. As a result, all share-based and cash payment obligations have been recorded as research and development expense in the accompanying condensed consolidated statements of operations and other comprehensive loss.

11. ~~Preferred and common~~Common stock

~~In January 2020, the Company authorized the designation of~~ ~~25,000,000~~ ~~shares of preferred stock and increased its authorized common stock to~~ ~~250,000,000~~ ~~shares, each with a par value of $0.01~~ ~~per share.~~

~~In February 2020, the Company completed its IPO in which the Company issued and sold~~ ~~12,176,471~~ ~~shares of its common stock, including~~ ~~1,588,235~~ ~~shares pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $17.00~~ ~~per share, for aggregate gross proceeds of $207.0~~ ~~million. The Company received approximately $188.3~~ million in net proceeds after deducting underwriting discounts and offering expenses payable by the Company. In connection with the IPO, all outstanding shares of the Company’s redeemable convertible preferred stock converted into ~~29,127,523~~ ~~shares of the Company’s common stock.~~

~~In October 2020, due to its election to continue the Prime Agreement, the Company issued~~ ~~200,307~~ ~~shares of its common stock to Prime Medicine.~~

In January 2021, the Company issued and sold 2,795,700 shares of its common stock in a private placement at an offering price of $93.00 per share for aggregate gross proceeds of $260.0 million. The Company received $252.0 million in net proceeds after deducting fees to the placement agents and offering expenses payable by the Company.

In April 2021, the Company entered into the Sales Agreement, with Jefferies, pursuant to which the Company was entitled to offer and sell, from time to time at prevailing market prices, shares of the Company’s common stock having aggregate gross proceeds of up to $300.0 million. The Company agreed to pay Jefferies a commission of up to 3.0% of the aggregate gross sale proceeds of any shares sold by Jefferies under the Sales Agreement. ~~As of September 30,~~Between April and July 2021, the Company has sold 2,908,009 shares of its common stock under the Sales Agreement at an average price of $103.16 per share for aggregate gross proceeds of $300.0 million, before deducting commissions and offering expenses payable by the Company.

In July 2021, the Company and Jefferies entered into an amendment to the Sales Agreement to provide for an increase in the aggregate offering amount under the Sales Agreement, such that as of July 7, 2021, the Company may offer and sell shares of common stock having an aggregate offering price of an additional $500.0 million. As of ~~September 30, 2021,~~March 31, 2022, the Company has sold ~~1,765,833~~2,873,956 additional shares of its common stock under the amended Sales Agreement at an average price of $~~107.88~~92.71 per share for aggregate gross proceeds of $~~190.5~~266.5 million, before deducting commissions and offering expenses payable by the ~~Company, resulting in an aggregate of $490.5~~ ~~million in gross proceeds received under the Sales Agreement as of September 30, 2021.~~

In May 2021, the first success payment measurements under each of the Harvard License Agreement and Broad Institute License Agreement occurred and success payments to Harvard and Broad Institute were calculated to be $~~15.0~~ ~~million and $15.0~~ ~~million, respectively. The Company elected to make each payment in shares of the Company’s common stock and issued~~ ~~174,825~~ ~~shares of the Company’s common stock to each of Harvard and Broad Institute to settle these liabilities in June 2021.~~Company.

The holders of the Company’s common stock are entitled to one vote for each share of common stock. Subject to the payment in full of all preferential dividends to which the holders of the Company’s preferred stock are entitled, the holders of the Company’s common stock shall be entitled to receive ratably dividends out of funds legally available. In the event of any voluntary or involuntary liquidation, dissolution, or winding up of the Company, after the payment or provision for payment of all debts and liabilities of the Company and all preferential amounts to which the holders of Company’s preferred stock are entitled with respect to the distribution of assets in liquidation, the holders of common stock shall be entitled to share ratably in the remaining assets of the Company available for distribution.

The weighted-average grant date fair value per share of options granted in the ~~nine~~three months ended ~~September 30, 2021~~March 31, 2022 was $~~58.85~~46.09. As of ~~September 30, 2021,~~March 31, 2022, there was $~~107.3~~158.4 million of unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of approximately ~~2.4~~2.6 years.

The Company issues shares of restricted common stock, including both restricted stock units and restricted stock awards. Restricted common stock issued generally vests over a period of two to four years.

At ~~September 30, 2021,~~March 31, 2022, there was approximately $~~74.5~~106.9 million of unrecognized stock-based compensation expense related to restricted stock that is expected to vest. These costs are expected to be recognized over a weighted-average remaining vesting period of approximately ~~2.7~~3.5 years.

In February 2020, the Company’s board of directors adopted the Beam Therapeutics Inc. 2019 Employee Stock Purchase Plan, or ESPP, which was approved by the Company’s stockholders. Pursuant to the ESPP, certain employees of the Company, excluding consultants and non-employee directors, are eligible to purchase common stock of the Company at a reduced rate during offering periods. The ESPP permits participants to purchase common stock using funds contributed through payroll deductions, subject to a calendar year limit of $25,000 and at a purchase price of 85% of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the applicable purchase date, which will be the final trading day of the applicable purchase period. The first offering period commenced on October 1, 2021. The Company issued 28,990 shares under the ESPP during the three months ended March 31, 2022. There were 0 shares issued under the ESPP during the three months ended March 31, 2021. As of ~~September 30, 2021,~~March 31, 2022, the Company had ~~1,049,460~~1,706,282 shares available for issuance under the ESPP.

The Company uses the straight-line attribution approach to record the expense over the offering period. Stock-based compensation for the ESPP for the three months ended March 31, 2022 was $0.3 million. There was 0 stock-based compensation expense recorded under the ESPP for the three months ended March 31, 2021.

14. Income taxes

During the three ~~and nine~~ months ended ~~September 30,~~March 31, 2022 and 2021, ~~and 2020,~~ the Company recorded a full valuation allowance on federal and state deferred tax assets since management does not forecast the Company to be in a taxable position in the near future.

15. Related party transactions

Founders

The Company made payments of $0.1 million and $~~0.3~~0.1 million to its 3 founder shareholders for scientific consulting and other expenses for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2022 and 2021, respectively.

Verve

The Company and Verve are parties to ~~the Verve Agreement~~a collaboration and license agreement and have a common board member.

Prior to Verve’s initial public offering in June 2021, the Company owned both common and preferred shares of Verve and valued such investment based on the cost of the equity securities adjusted for any observable market transactions. Following ~~the~~Verve’s initial public offering, and the conversion of the preferred stock to common stock and a stock split, the equity securities have a readily determinable fair ~~value; however, they are subject to transfer restrictions. Following the initial public offering,~~value and the Company owned 546,970 shares of Verve's common stock, the value of which is included in ~~long-term investments~~marketable securities in the condensed consolidated balance sheet. The Company recorded the investment at fair value as of ~~September 30, 2021,~~March 31, 2022, which resulted in ~~the~~a recognition ~~of $4.9~~ ~~million~~ of other expense ~~and~~of $~~22.0~~7.7 million during the three months ended March 31, 2022 . The Company recorded other income of $1.0 million ~~of other income~~ for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2021 ~~respectively.~~related to the changes in fair value of Verve's stock. The value of this investment as of ~~September 30, 2021~~March 31, 2022 is $~~24.4~~12.5 million.

~~During the nine months ended September 30, 2020, the Company purchased shares of Verve's series A preferred stock valued at $0.8~~ ~~million and recognized gains of $0.5~~ ~~million, which is recorded in other income, on its investment in Verve stock.~~

The Company purchased certain materials from Verve amounting to $0.2 million, which are recorded as research and development expenses within the accompanying condensed consolidated statements of operations and other comprehensive loss, for the ~~nine~~three months ended ~~September 30,~~March 31, 2021. The Company ~~purchased certain~~did 0t purchase any materials from Verve ~~amounting to $~~during the ~~0.3~~ ~~million for the nine~~three months ended ~~September 30, 2020. The Company also sold certain materials to Verve amounting to $0.2~~ ~~million for the nine months ended September 30, 2020.~~March 31, 2022.

In October 2021, the Company entered into an agreement pursuant to which Verve ~~will sublease~~subleased 12,000 square feet of ~~Beam's~~the Company’s existing office and laboratory space for a term of one year ~~beginning~~which began in December 2021. Verve is expected to pay approximately $1.4 million in rental payments over the term of the sublease, as well as its proportionate costs for the landlord’s operating expense, insurance, property taxes, and utilities. The Company recorded $0.3 million of sublease income related to this sublease within the accompanying consolidated statements of operations and other comprehensive loss for the three months ended March 31, 2022.

Prime Medicine

The Company and Prime Medicine are parties to the Prime Agreement and have a common founder and a common board member.

Additionally, in September 2019, in connection with the Prime Agreement, the Company executed a letter agreement, as amended, to provide certain interim management and startup services to Prime Medicine through March 2021. Prime Medicine was obligated to reimburse the Company’s out-of-pocket costs incurred in connection with performing these services and, beginning in October 2020 and ending in March 2021, paid the Company a $~~30,000~~30.0 thousand monthly service fee. ~~For~~There were no interim management and startup services provided to Prime Medicine during the ~~nine~~three months ended ~~September 30, 2021, the Company recognized $0.1~~ ~~million for performing such services in interest and other income (expense), net, within the accompanying consolidated statements of operations and other comprehensive loss.~~March 31, 2022.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and the related notes to those statements included elsewhere in this Quarterly Report on Form 10-Q. In addition to historical financial information, the following discussion and analysis contains forward-looking statements that involve important risks, uncertainties and assumptions. Some of the numbers included herein have been rounded for the convenience of presentation. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including those discussed in “Risk Factors” in Part II, Item 1A. and elsewhere in this Quarterly Report on Form 10-Q, and in ~~our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2021, and June 30, 2021, and in~~ the “Risk Factors Summary” and “Item 1A. Risk Factors” section of our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2020,~~2021, or the ~~2020~~2021 Form 10-K.

We are a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. Our vision is to provide life-long cures to patients suffering from serious diseases. To achieve this vision, we have assembled a platform that includes a suite of gene editing and delivery technologies and are in the process of developing internal manufacturing capabilities.

Our suite of gene editing technologies is anchored by our proprietary base editing technology, which potentially enables ~~an entirely new~~a differentiated class of precision genetic medicines that target a single base in the genome without making a double-stranded break in the DNA. This approach uses a chemical reaction designed to create precise, predictable and efficient genetic outcomes at the targeted sequence. Our ~~novel~~proprietary base editors have two principal components: (i) a clustered ~~regulatory~~regularly interspaced short palindromic repeats, or CRISPR, protein, bound to a guide RNA, that leverages the established DNA-targeting ability of CRISPR, but is modified to not cause a double-stranded break, and (ii) a base editing enzyme, such as a deaminase, which carries out the desired chemical modification of the target DNA base. We believe this design contributes to a more precise and efficient edit compared to traditional gene editing methods, which operate by creating targeted double-stranded breaks in the ~~DNA; these breaks~~DNA that can result in unwanted DNA modifications. We believe that the precision of our editors will dramatically increase the impact of gene editing for a broad range of therapeutic applications.

To unlock the full potential of our base editing technology across a wide range of therapeutic applications, we are pursuing a broad suite of both clinically validated and novel delivery ~~modalities. For a given~~modalities, depending on tissue type, ~~we use the delivery modality with the most compelling biodistribution. Our current programs utilize three different delivery modalities:~~including: (1) electroporation for efficient delivery to blood cells and immune cells ex ~~vivo~~;vivo; (2) lipid nanoparticles, or LNPs, for non-viral in vivo delivery to the liver and potentially other organs in the future; and (3) adeno-associated viral vectors, or AAV, for in vivo viral delivery to the ~~eye.~~eye and potentially other organs.

The elegance of the base editing approach combined with a tissue specific delivery modality provides the basis for a targeted efficient, precise, and highly versatile gene editing system, capable of gene correction, gene modification, gene silencing or gene activation, and/or multiplex editing of several genes simultaneously. We are currently advancing a broad, diversified portfolio of base editing programs against distinct editing targets, utilizing the full range of our development capabilities. ~~We believe~~

Furthermore, in addition to our portfolio, we are also pursuing an innovative, platform-based business model with the ~~flexibility~~goal of further expanding our access to new technologies in genetic medicine and ~~versatility~~increasing the reach of our ~~base editors~~programs to more patients. Overall, we are seeking to build the leading integrated platform for precision genetic medicine, which may ~~lead to~~have broad therapeutic applicability and ~~transformational~~the potential ~~for~~to transform the field of precision genetic medicines.

We believe that building an integrated platform combining our gene editing capabilities with advanced delivery and manufacturing capabilities will give us the maximum flexibility to develop our own sustainable portfolio and to create a hub for partnering with other companies to unlock the full potential of precision genetic medicine across all possible applications.Ex Vivo

We are advancing ex vivo base editing programs in which hematopoietic stem cells, or HSCs are collected from a patient, edited using electroporation, a clinically validated technology for the delivery of therapeutic constructs into harvested cells. These cells are infused back into the patient following a myeloablative conditioning regimen, such as treatment with busulfan, the standard of care in HSC transplantation today. Once reinfused, the HSCs begin repopulating a portion of the bone marrow in a process known as engraftment. The engrafted, edited HSCs give rise to progenitor cell types with the corrected gene sequences.

We are pursuing a long-term, staged development strategy for our base editing approach to treat sickle cell disease that consists of advancing our ex vivo programs, BEAM-101 and BEAM-102, in Wave 1, improving patient conditioning regimens in Wave 2, and enabling in vivo base editing with delivery directly into HSCs of patients via LNPs in Wave 3. We believe this suite of technologies – base editing, improved conditioning and in vivo delivery for editing HSCs – can maximize the potential applicability of our sickle cell disease programs to patients as well as create a platform for the treatment of many other severe genetic blood disorders

Wave 1: Ex Vivo Base Editing via Autologous Transplant with BEAM-101 and BEAM-102

We are using base editing to pursue the development of two complementary approaches to treating sickle cell disease, a severe inherited blood disease caused by a single point mutation, E6V, in the beta globin gene (BEAM-101 and BEAM-102), and one approach to treat beta-thalassemia, another inherited blood disorder characterized by severe anemia caused by reduced production of functional hemoglobin due to insufficient expression of the beta globin protein (BEAM-101).

BEAM-101: Recreating naturally-occurring protective mutations to activate fetal hemoglobin

In November 2021, we announced that our Investigational New Drug, or IND, application for BEAM-101 for the treatment of sickle cell disease was cleared by the U.S. Food and Drug Administration, or FDA. BEAM-101 is an investigational, a patient-specific, autologous hematopoietic ~~investigational~~ cell therapy which ~~was~~is designed to incorporate ex vivo base edits that mimic single nucleotide polymorphisms seen in individuals with hereditary persistence of fetal hemoglobin, or HPFH, to potentially alleviate the effects of mutations causing sickle cell disease or beta thalassemia. WeOur Investigational New Drug, or IND, application for BEAM-101 for the treatment of sickle cell disease has been cleared by the U.S. Food and Drug Administration, or FDA, and we are preparing to initiate a Phase 1/2 clinical trial designed to assess the safety and efficacy of BEAM-101 for the treatment of sickle cell disease, which we refer to as our BEACON-101 trial. The BEACON-101 trial is expected to include an initial “sentinel” cohort of three patients, treated one at a time to confirm successful engraftment, followed by dosing in up to a total of 45 patients. The clinical trial is designed to initially include patients between ages 18 and 35 with sickle cell disease who have received prior treatment with at least one disease-modifying agent with inadequate response or intolerance. Following mobilization, conditioning and HSC transplant with BEAM-101, patients will be assessed for safety and tolerability, with safety endpoints including the proportion of patients with successful neutrophil engraftment by day 42. Patients will also be assessed for efficacy, with efficacy endpoints including the change from baseline in severe vaso-occlusive events, transfusion requirements, hemoglobin F levels, and quality of life and ability to function. We have begun site selection and the institutional review board approval processes for the BEACON-101 trial and plan to enroll the first subject in the second half of 2022.

We have achieved proof-of-concept in vivo with long-term engraftment of base edited human CD34 cells in mice ~~for~~administered BEAM-101. Persistence of engraftment and high levels of editing have been confirmed in several preclinical studies, including in studies using material generated at a clinically relevant scale.

Our second ex vivo base editing approach that we are developing for sickle cell disease, BEAM-102, is ~~a direct correction of~~designed to directly correct the causative sickle mutation at position 6 of the beta globin gene. This approach has been enabled by our inlaid base editors, or IBEs, which are architectural variants of base editors that have attributes of enhanced specificity and altered activity windows relative to foundational base editors. Our IBEs expand the breadth of potential base editing targets by extending the range of editing windows that can be created for any given CRISPR protein used to target the DNA. By inserting the deaminase into the CRISPR protein at various strategic positions, thereby repositioning the deaminase’s editing window, IBEs enable editing outside the traditional editing window. BEAM-102 directly corrects the causative mutation in sickle cell disease by recreating a naturally-occurring normal human hemoglobin variant, HbG-Makassar. By making a single A-to-G edit, we have demonstrated in primary human CD34+ cells isolated from sickle cell disease patients the ability to create the naturally occurring ~~Makassar~~HbG or “Makassar” variant of hemoglobin. This variant, which was identified in humans and first published in 1970, has the same function as the wild-type variant and does not cause sickle cell disease. Distinct from other approaches, cells that are successfully edited in this way are fully corrected, no longer containing the sickle protein. We have initiated IND-enabling studies for BEAM-102 and expect to submit an IND to the FDA for the treatment of sickle cell disease during the second half of 2022.

During the second quarter of 2020, we published preclinical data on BEAM-102 demonstrating that our adenine base editors, or ABEs, can efficiently convert the causative Hemoglobin S, or HbS, point mutation, to HbG-Makassar, with high efficiency (more than 80%). In this preclinical study, the Makassar variant does not cause hemoglobin to polymerize and red blood cells to sickle and, therefore, edited cells are cured through elimination of the disease-causing protein. ~~The results~~In December 2021, we presented data from preclinical studies further characterizing the Makassar hemoglobin created by BEAM-102 and demonstrating biophysical and biochemical properties consistent with normal hemoglobin.

In parallel with Wave 1 development, we also aim to improve the transplant conditioning regimen for sickle cell disease patients undergoing HSCT, reducing toxicity challenges associated with HSCT standard of care. Conditioning is a critical component necessary to prepare a patient’s body to receive the ex vivo edited cells that must engraft in the patient’s bone marrow in order to be effective. Today’s conditioning regimens rely on nonspecific chemotherapy or radiation, which are associated with significant toxicities. We are collaborating with Magenta Therapeutics, Inc., or Magenta, to evaluate the potential utility of MGTA-117, Magenta’s novel antibody drug conjugate, in combination with BEAM-101 and BEAM-102, as well as other base editing programs in hematology. MGTA-117 is designed to spare immune cells and precisely target hematopoietic stem and progenitor cells, or HSPCs, and has demonstrated high selectivity, potent efficacy, wide safety margins and broad tolerability in non-human primate, or NHP, models. We are also conducting our own research into novel conditioning strategies. Improved conditioning regimens could potentially be paired with BEAM-101 and BEAM-102, as well as other base editing programs in hematology.

We are also exploring the potential for in vivo base editing programs for sickle cell disease, in which base editors would be delivered to the patient through an infusion of LNPs targeted to HSCs, eliminating the need for transplantation altogether. This approach could provide a more accessible option for patients, particularly in regions where ex vivo treatment is challenging. Building on our acquisition of Guide, we are using our proprietary DNA-barcoded LNP screening technology to enable high-throughput in vivo identification of LNPs with novel biodistribution and selectivity for target organs beyond the liver. In December 2021, we announced

we had screened more than 1,000 LNPs using this ~~study confirmed~~technology for potential to deliver to HSCs and had identified LNP-HSC1 as the ~~ability~~most potent, with efficient transfection in both mice and NHPs.

Achieving Understanding of the ~~Makassar variant~~Natural History of Sickle Trait (AUNT) Study

In May 2022, we announced the initiation of a sickle cell trait, or SCT, focused natural history study. Carriers of sickle cell disease, or those with SCT, have only one copy of the hemoglobin gene, have HbS levels between 25-45%, and are thought to ~~protect~~have a benign condition. However, despite SCT impacting approximately 300 million people around the world, the key hematologic and clinical phenotypic characteristics and functional impacts from having SCT have been understudied in a prospective manner. As part of a long-term lifecycle strategy for our sickle cell disease programs, we, in collaboration with the National Alliance of Sickle Cell Centers, the University of Alabama, and Johns Hopkins Medical Center, have initiated the AUNT (Achieving Understanding of the Natural History of Sickle Trait) Study.

The AUNT Study is designed to establish an understanding of the hematologic and clinical phenotype of people with SCT, including blood rheology, potential complications and genetic modifiers, in an effort to better understand the hematologic phenotype that is associated with good health and lack of organ dysfunction. The study is designed to enroll approximately 1,000 participants with SCT in the United States who have been identified as family members of participants in the Global Research Network for Data and Discovery, a multi-institutional prospective registry comprising clinical and background data from more than 1,200 adult and pediatric individuals with sickle cell disease from 1999-2021.

The starting material for our multiplex-edited allogeneic CAR-T cell products is white blood cells from ~~sickling, even in~~a healthy donor, which are collected using a standard blood bank procedure known as leukapheresis. Using a single electroporation, we introduce the ~~context of mono-allelic editing (with one sickle allele~~base editor as mRNA, and ~~one corrected allele). In November 2021, we announced that we initiated IND-enabling studies for BEAM-102.~~the guides encoding the target sequences. The edited cells are subsequently transduced with a lentivirus expressing the CAR. Once the T cells have been engineered, they are expanded and frozen. After the patient is lymphodepleted, the multiplex-edited, allogenic cell product is infused.

~~Oncology:~~We believe base editing is a powerful tool to simultaneously multiplex edit many genes without the unintended on-target effects that can result from simultaneous editing with nucleases through the creation of double-stranded breaks. The ability to create a large number of multiplex edits in T cells could endow CAR-T cells and other cell therapies with combinations of features that have the potential to dramatically enhance their therapeutic potential in treating hematological or solid tumors.

The initial indications that we plan to target with our chimeric antigen receptor T-cell, or CAR-T, product candidates are relapsed, refractory T-cell acute lymphoblastic leukemia /T cell lymphoblastic lymphoma, or ~~T-ALL,~~T-ALL/T-LL, a severe disease affecting children and adults, and Acute Myeloid Leukemia, or AML. We believe that our approach has the potential to produce higher response rates and deeper remissions than existing approaches. Our proof-of-concept ~~pre-clinical experiments~~preclinical studies have demonstrated the ability of base editors to efficiently modify up to 8eight genomic loci simultaneously in primary human T cells with efficiencies ranging from 85-95% as measured by flow cytometry of target protein knockdown. Importantly, these results were achieved without the generation of observed chromosomal rearrangements, as ~~detected~~evaluated by sensitive methods such as UDiTaSTMor G-banded Karyotyping and with no observed loss of cell viability from editing. ~~Our~~The proof-of-concept ~~experiments~~preclinical studies have also demonstrated robust ~~T-cell~~T cell killing of target tumor cells both in vitro and in vivo. We plan to nominate a second CAR-T development candidate, in addition to BEAM-201, in 2022.

BEAM-201 is ~~our potent and specific anti-CD7, multiplex edited, allogeneic CAR-T~~a development candidate ~~for the treatment~~comprised of ~~relapsed/refractory T-ALL. BEAM-201 is produced using a Good Manufacturing Practice, or cGMP, compliant, clinical-scale process in which T-cells~~T cells derived from healthy donors that are simultaneously ~~base~~ edited at ~~four genomic loci,~~TRAC, CD7, CD52 and PDCD1 and then transduced with a lentivirus ~~coding~~encoding for an anti-CD7 ~~CAR. The resulting cells are universally-compatible, allogeneic (“off the shelf”) CD7-targeting~~CAR that is designed to create allogenic CD7 targeting CAR-T cells, resistant to both fratricide and immunosuppression. To our knowledge, BEAM-201 is the first investigational cell therapy featuring four simultaneous edits. ~~In August 2021, we announced that we had~~We have initiated IND-enabling studies for ~~BEAM-201.~~BEAM-201 and expect to submit an IND to the FDA for the treatment of relapsed, refractory T-ALL/T-LL and potentially other CD7+ malignancies during the second half of 2022.

In October 2021, we announced preclinical data from our multiplex edited allogeneic ~~CAR T~~CAR-T research program targeting CD5-positive hematologic ~~malignancies which we intend to present later this year. This~~malignancies. These data demonstrated knockout of CD5 expression to be a general mechanism to enhance potency and potentially improve durability of highly multiplexed ~~CAR T~~CAR-T cells.

LNPs are a clinically validated technology for delivery of nucleic acid payloads to the liver. LNPs are multi-component particles that encapsulate the base editor mRNA and one or more guides and protect them from degradation while in an external environment, enabling the transient delivery of the base editor in vivo. Multiple third-party clinical trials have demonstrated the effective delivery of silencing RNA to the liver using LNPs. Because only one dose of a base editing therapy may be needed in a course of treatment, LNPs are a suitable delivery modality that we believe is unlikely to face the complications seen with chronic use of LNPs, such as those

observed when delivering oligonucleotides or mRNA for gene therapy. All of the components of the LNP, as well as the mRNA encoding the base editor, are well-defined and can be manufactured synthetically, providing the opportunity for scalable manufacturing.

We have developed several proprietary LNP formulations. In May 2021, we announced initial data from our evaluation of various LNP formulations and mRNA production processes using an mRNA-encoding ABE and guide RNA to target the ALAS1 gene, a surrogate payload for genetic liver diseases. These data showed improved in vivo editing in the livers of NHPs from less than 10% initially to 52% at a total RNA dose of 1.5 mg/kg. Continued optimization of our LNP formulations has demonstrated further increases in liver editing potency in NHPs. In September 2021, we presented data demonstrating up to 60% editing in NHPs at a total RNA dose of 1.0 mg/kg. Data from our preclinical studies demonstrated that these formulations were well tolerated by NHPs treated with doses up to 1.5 mg/kg. Minimal to mild and transient liver enzyme elevations were observed and resolved by day 15 post-treatment. Additionally, the formulations showed promising interim stability, maintaining potency after three months at -20⁰C and -80⁰C.

We are currently using LNP formulations to advance our programs for genetic liver diseases, including Glycogen Storage Disease Type Ia, or GSDIa, also known as Von Gierke disease, and Alpha-1 Antitrypsin Deficiency, or Alpha-1, and chronic hepatitis B infection. In December 2021, we nominated BEAM-301, a liver-targeting LNP formulation of base editing reagents designed to correct the R83C mutation, the most common disease-causing mutation of GSDIa, as our first in vivo development candidate. We anticipate initiating IND-enabling studies for BEAM-301 and nominating a second liver-targeted development candidate in 2022.

Liver diseases: ~~Alpha-1 antitrypsin deficiency,~~ glycogen storage disorder 1a, alpha-1 antitrypsin deficiency, and chronic hepatitis B infection

GSDIa is an inborn disorder of glucose metabolism caused by mutations in the G6PC gene, which results in low blood glucose levels that can be fatal if patients do not adhere to a strict regimen of slow-release forms of glucose, administered every one to four hours (including overnight). There are no disease modifying therapies available for patients with GSDIa.

Our approach to treating patients with GSDIa is to apply base editing via LNP delivery to repair the two most prevalent mutations that cause the disease, R83C and Q347X. It is estimated that these two point mutations account for 900 and 500 patients, respectively, in the United States, representing approximately 59% of all GSDIa patients in the United States. Third party animal studies have shown that as little as 11% of normal G6Pase activity in liver cells is sufficient to restore fasting glucose; however, this level must be maintained in order to preserve glucose control and alleviate other serious, and potentially fatal, GSDIa sequelae.

In October 2021, we reported data from preclinical studies that support the potential of base editing to durably correct disease-causing mutations of GSDIa. We ~~are currently using~~created a ~~variety~~novel, humanized R83C knockout mouse model (huR83C), mimicking the abnormal metabolic phenotype of ~~cationic lipids~~human GSDIa, and collaborated with the National Institutes of Health, or NIH, to characterize the phenotype of these animals. The results demonstrated that newborn huR83C mice treated with our LNP-delivered ABE exhibited normal growth to the end of the study at three weeks of age without any hypoglycemia-induced seizures. In contrast, homozygous animals were unable to survive soon after birth in the absence of glucose supplementation. In addition, we observed editing efficiencies up to approximately 60% by next-generation sequencing of DNA isolated from ~~various sources~~the whole liver.

In May 2022, an abstract announcing new preclinical data to ~~advance our programs for liver diseases,~~be presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting was published. The data, which ~~include Alpha-1 Antitrypsin Deficiency, or Alpha-1, Glycogen Storage Disease Type IA, or~~build on previously released preclinical results, demonstrated that in a GSDIa ~~(also known~~mouse model, treated mice, which otherwise have poor survival outcomes if left untreated, grew normally to at least 35 weeks following administration of BEAM-301, with survival ongoing in the study. Notably, as ~~Von Gierke disease)~~low as single digit percentage base-editing rates were sufficient to restore physiologically relevant levels of hepatic G6Pase activity, normalize serum metabolites and, ~~chronic hepatitis B infection.~~most importantly, prevent hypoglycemia during a twenty-four hour fast in treated mice. In addition, preliminary assessments of observed off-target editing have suggested a favorable profile of BEAM-301.

Alpha-1 is a severe inherited genetic disorder that can cause progressive lung and liver disease. The most severe form of Alpha-1 arises when a patient has a point mutation in both copies of the SERPINA1 gene at amino acid 342 position (E342K, also known as the PiZ mutation or the “Z” allele). With the high efficiency and precision of our base editors, we aim to utilize our ABEs to enable the programmable conversion of A-to-T and G-to-C base pairs and precisely correct the E342K point mutation back to the wild type sequence. In 2020, we showed the ability to directly correct the mutation causing Alpha-1, providing both in vitro and in vivo preclinical proof-of-concept for base editing to correct this disease.

~~GSDIa is~~In May 2022, an ~~inborn disorder of glucose metabolism caused by mutations in~~abstract to be presented at ASGCT detailed our efforts to optimize both the ~~G6PC gene, which results in low blood glucose levels that can be fatal if patients do not adhere~~ABE and the guide RNA used to correct the disease-causing PiZ mutation, with improvements over the original reagents leading to a ~~strict regimen of slow-release forms of glucose, administered every one~~greater than two-fold increase in observed editing potency and potentially therapeutically relevant increases in circulating alpha-1 antitrypsin in mice treated at doses that are expected to ~~four hours (including overnight)~~be clinically relevant (<1mg/kg). ~~Our approach~~Further, similar results were observed in adult mice dosed at greater than 37 weeks, a treatment context more similar to treating patients with GSDIa is to apply base editing using lipid nanoparticle, or LNP, delivery to repair the two most prevalent mutations that cause the disease, R83C and Q347X. We have achieved editing levels what might be encountered in ~~vivo, in~~a clinical setting.

preclinical models, for the correction of the two most prevalent mutations causing GSDIa, which could be clinically relevant if reproduced in humans. Additionally, in October 2021, we presented new preclinical data demonstrating the ability of our liver-targeted base editing approach to directly correct R83C. To evaluate this approach, we created a novel humanized GSDIa R83C knockout mouse model in collaboration with the National Institutes of Health, or NIH, which mimicked the abnormal metabolic phenotype of human GSDIa. These data demonstrated that newborn huR38C mice treated with our LNP-delivered adenine base editors, or ABEs, exhibited normal growth to the end of the study at three weeks of age without any hypoglycemia-induced seizures. In contrast, homozygous animals were unable to survive soon after birth in the absence of glucose supplementation. In addition, we observed editing efficiencies up to approximately 60% by next generation sequencing of DNA isolated from the whole liver. Published studies suggest that a critical therapeutic threshold of approximately 11% of normal G6Pase activity in the liver is sufficient to mitigate fasting~~hypoglycemia in animal models of GSDIa. Based on these preclinical data and our LNP formulation progress discussed below, we expect to nominate our first development candidate for~~ ~~in vivo~~ ~~base editing in the liver using LNP delivery for the treatment of patients with GSDIa (R83C mutation) by the end of 2021.~~

Hepatitis B virus, or HBV, causes serious liver infection that can become chronic, increasing the risk of developing life-threatening health issues like cirrhosis, liver failure or liver cancer. Chronic HBV infection is characterized by the persistence of covalently closed circular DNA, or cccDNA, a unique DNA structure that forms in response to HBV infection in the nuclei of liver cells. Additionally, the HBV DNA can integrate into the human genome becoming a source of hepatitis B surface antigen, or HBsAg. While currently available treatments can manage HBV replication, they do not clear cccDNA from the infected liver cells. This inability to prevent HBV infection rebound from cccDNA is a key challenge to curing HBV. In September 2021, we presented preclinical data ~~demonstrating~~that demonstrated the potential of our cytosine base editors to reduce viral markers, including HBsAg expression, and prevent viral rebound of HBV in in vitro models.

AAV is a clinically validated technology that has been extensively used for gene delivery to a variety of tissues. AAV is a small, non-pathogenic virus that can be repurposed to carry a therapeutic payload, making it a suitable vector for delivery of gene editing therapies. Several clinical trials have been conducted or are in progress with different AAV variants for multiple diseases, including diseases of the eye, liver, muscle, lung and central nervous system. We have an option to in-license a variety of AAV variants that could be selected for optimal distribution to multiple organs. Because our ~~liver disease programs~~DNA base editors are larger than the approximate 4.5kb packaging limit of AAV vectors, we use a novel split intein technology that is finalizing our LNP formulation, and we are making progress on developing a formulation using proof-of-concept targets. In May 2021, we announced initial data from our evaluation of various LNP formulations and mRNA production processes using an mRNA-encoding ABEdesigned to deliver the base editor and guide RNA ~~to target~~by co-infection with two viruses, where each virus contains approximately one half of the ~~ALAS1 gene, a surrogate payload for genetic liver diseases. These data showed improved~~ ~~in vivo~~ editing in the livers of non-human primates, or NHPs, from less than 10% initially to 52% at a total RNA dose of 1.5 mg/kg. Continued optimization of our LNP formulations has demonstrated further increases in liver editing potency in NHPs. In September 2021, we presented data demonstrating up to 60% editing at a total RNA dose of 1.0 mg/kg. Data from our studies demonstrated that these formulations were well tolerated by NHPs treated with doses up to 1.5 mg/kg. Minimal to mild and transient liver enzyme elevations were observed and resolved by day 15 post-treatment. Additionally, the formulations showed promising interim stability, maintaining potency after three months at -20⁰C and -80⁰C. These and other LNP advances continue to give us confidence in our delivery to the liver and support our advances towards identifying and selecting future development candidates.editor.

We are currently evaluating AAV technology to correct one of the most prevalent mutations in the ABCA4 gene causing Stargardt disease, a progressive macular ~~degeneration.~~degeneration disease. This mutation is known as the G1961E point ~~mutation.~~mutation and approximately 5,500 individuals in the United States are affected.

~~Our base editing approach is to repair the G1961E point mutation in the ABCA4 gene.~~ Disease modeling using tiny ~~spot stimuli, or~~ light stimuli through holes that are equivalent in size to a single photoreceptor cell, suggests that only 12%-20% of these cells are ~~sufficient~~necessary to preserve vision. We anticipate, therefore, that editing percentages in the range of 12%-20% of these cells would be disease-modifying, since each edited cell will be fully corrected and protected from the biochemical ~~defect.~~defect associated with Stargardt disease.

We have identified a base editor that is able to edit approximately 45% of the alleles in recombinant cells carrying the human mutated sequence. Given that the base editor is larger than the packaging capacity of a single AAV, we use a split AAV system that delivers the base editor via two AAV vectors. Once inside the cell, the two halves of the editor are recombined to create a functional base editor. In a human retinal pigment epithelial cell line (ARPE-19 cells) in which we have knocked in the ABCA4 G1961E point mutation, we have demonstrated the precise correction of approximately 75% of the disease alleles at 5five weeks after dual infection with the split AAV system. In November 2021, we announced that we have initiated preclinical studies in NHPs for our Stargardt program.

To complement our next-generation gene editing technologies, we are also making significant investments in a broad suite of delivery technologies designed to deliver ~~our~~ gene editing or other nucleic acid payloads to the right cells toand enable potentially curative therapy. These delivery technologies include ex vivoelectroporation, nonviral vectors such as LNPs, and viral vectors such as AAVs. In our pipeline, we have initially focused on applications of these technologies ~~that are~~where their delivery capabilities have already been clinically-validated by third parties, such as ex vivo editing of blood stem cells orand LNP delivery to the liver. Longer term, we are also investing in more innovative delivery options, such as LNPs that could target other organs beyond the liver, or novel viral vectors beyond AAV. We have also developed critical enabling capabilities such as mRNA manufacturing and cell processing for autologous and allogeneic cell therapy.

Consistent with this approach, our acquisition of Guide Therapeutics, Inc., or Guide, ~~expands~~expanded our ability to explore new tissues and disease indications with our editing technologies. With Guide’s proprietary screening technology, which utilizes DNA barcodes to enable

high throughput in vivo LNP screening, ~~provides us with access to an existing~~we have a broad library of lipids and lipid formulations, and ~~the ability to generate~~we have generated additional novel LNPs that we believe ~~could~~can accelerate novel nonviral delivery of gene editing or other nucleic acid payloads to tissues beyond the liver. ~~In September 2021,~~For example, we ~~provided an update on our strategy for developing LNPs to deliver base editors to tissues beyond the liver, including hematopoietic stem and progenitor cells, or HSPCs. Leveraging~~have used our DNA barcoding technology ~~we identified~~to identify a family of LNPs for delivery of base editors to HSPCs in mice, ~~with administration at 1.0 mg/kg leading to 40% expression of mRNA cargo in cells. We are evaluating this delivery approach for potential application in hemoglobinopathies~~ and ~~other genetic blood disorders. In November 2021,~~ we ~~announced that we utilized our DNA barcoding technology to screen~~have screened more than 1,000 LNPs ~~and identified LNP-HSC1 as the most potent. LNP-HSC1 was validated~~ ~~in vivo, leading~~ to identify LNPs that achieve durable, dose-dependent mRNA transfection in HSPCs ~~of more than 40%, which was maintained for 10 weeks post-delivery. Further, LNP-HSC1 efficiently transfected~~in mice ~~at doses ranging from 0.3 mg/kg to 1.0 mg/kg,~~ and NHPs in ~~NHPs, a dose-dependent increase in mRNA in bone marrow-derived CD34+ HSPCs was observed.~~

We believe our base editing technology has potential across a broad array of genetic diseases. To fully realize this potential, we have established and will continue to seek out innovative collaborations, licenses, and strategic alliances with pioneering companies and with leading academic and research institutions. Additionally, we have and will continue to pursue relationships that potentially allow us to accelerate our preclinical research and development efforts. These relationships will allow us to aggressively pursue our vision of maximizing the potential of base editing to provide life-long cures for patients suffering from serious diseases.

In October 2021, we entered into an option and license agreement with Sana Biotechnology, Inc., or Sana, pursuant to which we granted Sana non-exclusive commercial rights to our CRISPR Cas12b nuclease system for certain ~~ex vivo~~ engineered cell therapy programs. Cas12b is a CRISPR-based nuclease with a high degree of specificity and efficiency that can be used to knock out and/or knock in genes in certain cell types. Under the terms of the agreement, Sana received non-exclusive rights to utilize our Cas12b system with certain allogeneic T cell and stem cell-derived programs. The agreement excludes any rights to base editing using our Cas12b system, which commercial rights remain with Beam. Under the terms of the agreement, Sana made a $50.0 million upfront payment to us in cash in October 2021. According to the terms of our May 2018 license agreement with The Broad Institute, Inc., or Broad Institute, we owe certain sublicense fees to Broad Institute on the upfront payment. We are also eligible to receive certain target option exercise fees, milestone payments upon the achievement of certain development and commercial sale milestones, and royalties on net sales of royalty-bearing products by Sana.

In July 2020, we formed a strategic alliance with Boston Children’s Hospital, or Boston Children’s. Under the terms of the agreement, we will sponsor research programs at Boston Children’s to facilitate development of disease-specific therapies using our proprietary base editing technology. Boston Children’s will also serve as a clinical site to advance bench-to-bedside translation of our pipeline across certain therapeutic areas of interest, including programs in sickle cell disease and pediatric leukemias and exploration of new programs targeting other diseases.

In June 2020, we announced a non-exclusive research and clinical collaboration agreement with Magenta Therapeutics Inc., or Magenta, to evaluate the potential utility of MGTA-117, Magenta’s novel targeted antibody-drug conjugate, for conditioning of patients with sickle cell disease and beta-thalassemia receiving our base editing therapies. Conditioning is a critical component necessary to prepare a patient’s body to receive the edited cells, which carry the corrected gene and must engraft in the patient’s bone marrow in order to be effective. Today’s conditioning regimens rely on nonspecific chemotherapy or radiation, which are associated with significant toxicities. MGTA-117 is designed to precisely target only hematopoietic stem and progenitor cells, to spare immune cells, and has shown high selectivity, potent efficacy, wide safety margins and broad tolerability in non-human primate models. MGTA-117 may be capable of clearing space in bone marrow to support long-term engraftment and rapid recovery in patients. Combining the precision of our base editing technology with the more targeted conditioning regimen enabled by MGTA-117 has the potential to further improve therapeutic outcomes for patients suffering from these severe diseases. We will be responsible for clinical trial costs related to development of our base editors when combined with MGTA-117, while Magenta will continue to be responsible for all other development costs of MGTA-117.

In April 2019, we entered into a collaboration and license agreement, or the Verve Agreement, with Verve Therapeutics Inc., or Verve, a company focused on developing genetic medicines to safely edit the genome of adults to permanently lower LDL cholesterol and triglyceride levels and thereby treat coronary heart disease. This collaboration allows us to more fully realize the potential of base

editing in treating cardiovascular diseases, an area outside of our core focus where the Verve team has significant expertise. Under the terms of the Verve Agreement, Verve received exclusive access to our base editing technology, gene editing, and delivery technologies for human therapeutic applications against certain cardiovascular targets. In exchange, we received shares of Verve common stock. Additionally, we will receive milestone payments for certain clinical and regulatory events and we retain the option, after the completion of Phase 1 studies, to participate in future development and commercialization, and share 50 percent of U.S. profits and losses, for any product directed against these targets. Verve granted to us a non-exclusive license under know-how and patents controlled by Verve, and an interest in joint collaboration technology. Either party may owe the other party other milestone payments for certain clinical and regulatory events related to the delivery technology products. Royalty payments may become due by either party to the other based on the net sales of any commercialized delivery technology products under the agreement. Per the terms of the Verve Agreement, we can exercise our right to participate in the future development and commercialization of any programs at the completion of Phase 1 studies.

In January 2021, Verve announced it had selected VERVE-101 as its lead product to be developed initially for the treatment of heterozygous familial hypercholesterolemia, or HeFH, a potentially fatal genetic heart disease. Individuals with HeFH have a genetic mutation causing extremely high LDL-C levels in the blood. Over time, high LDL-C builds up in the heart’s arteries, resulting in reduced blood flow or blockage, and ultimately heart attack or stroke. Inactivation of the proprotein convertase subtilisin/kexin type 9, or PCSK9, gene has been shown to up-regulate LDL receptor expression, which leads to lower LDL-C levels. By making a single A-to-G change in the DNA genetic sequence of PCSK9, VERVE-101 aims to inactivate the target gene.

In January 2021, Verve also reported additional preclinical proof-of-concept data in non-human primates that demonstrated the successful use of ABEs to turn off PCSK9. Utilizing ABE technology licensed from us and an optimized guide RNA packaged in an engineered LNP, Verve announced data demonstrating that ~~in vivo~~ base editing of the PCSK9 gene in the liver of non-human primates resulted in durable and consistent lowering of blood LDL-C and blood PCSK9 protein levels following a single course of treatment. In its pre-clinical studies, Verve reported that a single intravenous infusion achieved a 59% reduction in blood LDL-C at two weeks, which was maintained at six months post treatment, and that LDL-C reduction over this time period averaged 61%. Verve also disclosed that during this same six-month time period, the average blood PCSK9 protein level was reduced by 89%. Verve further reported that the treatment was well tolerated with no adverse events reported during the study and that in studies of primary human hepatocytes, clear evidence of on-target editing was observed with no evidence of off-target editing.

Verve announced the closing of its initial public offering in June 2021, at which time we owned 546,970 shares of its common stock. Following the initial public offering, the equity securities are included in long-term investments on the consolidated balance sheet. We recorded the investment at fair value as of September 30, 2021, which resulted in of the recognition of $4.9 million of other expense and $22.0 million of other income for the three and nine months ended September 30, 2021, respectively. During the nine months ended September 30, 2020, we recognized gains of $0.5 million, which is recorded in other income, on our investment in Verve stock. The value of this investment as of September 30, 2021 is $24.4 million.

In July 2020, we announced a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel, or IOB. Founded in 2018 by a consortium that includes Novartis, the University Hospital of Basel and the University of Basel, IOB is a leader in basic and translational research aimed at treating impaired vision and blindness. Clinical scientists at IOB have also helped to develop better ways to measure how vision is impacted by Stargardt disease.

Additionally, researchers at IOB have developed living models of the retina, known as organoids, which can be used to test novel therapies. Under the terms of the agreement, the companies will leverage IOB’s unique expertise in the field of ophthalmology along with our novel base editing technology to advance programs directed to the treatment of certain ocular diseases, including Stargardt disease.

In June 2021, we entered into a research collaboration agreement, or the Apellis Agreement, with Apellis Pharmaceuticals, Inc., or Apellis, focused on the use of certain of our base editing technology to discover new treatments for complement system-driven diseases. Under the terms of the Apellis Agreement, we will supply certain of our base editing technology and conduct preclinical research on up to six base editing programs that target specific genes within the complement system in various organs, including the eye, liver, and brain. Apellis will have exclusive rights to license each of the six programs and will assume responsibility for subsequent development. We may elect to enter into a 50-50 U.S. co-development and co-commercialization agreement with Apellis with respect to one program licensed under the collaboration.

As part of the collaboration, we are eligible to receive a total of $75.0 million in upfront and near-term milestones from Apellis, which is comprised of $50.0 million received upon signing and an additional $25.0 million payment on June 30, 2022, the one-year

anniversary of the signing date of the Apellis Agreement. Following any exercise of the opt-in license rights for any of the six programs, we will be eligible to receive development, regulatory, and sales milestones from Apellis, as well as royalty payments on sales. The collaboration has an initial term of five years and may be extended up to two years on a per year and program-by-program basis. We received the $50.0 million initial payment in July 2021. According to the terms of our June 2017 license agreement with Harvard University, or Harvard, we owe certain sublicense fees to Harvard on the upfront payment.

To realize the full potential of base editors as a ~~new~~differentiated class of medicines and to enable our parallel investment strategy in multiple delivery modalities, we are building customized and integrated capabilities across discovery, manufacturing, and preclinical and clinical development. Due to the critical importance of high-quality manufacturing and control of production timing and know-how, we have taken steps toward establishing our own manufacturing facility, which will provide us the flexibility to manufacture a variety of different product modalities. We believe this investment will maximize the value of our portfolio and capabilities, the probability of technical success of our programs, and the speed at which we can provide potentially life-long cures to patients.

In August 2020, we entered into a lease agreement with Alexandria Real Estate Equities, Inc. to build a 100,000 square foot current cGMP compliant manufacturing facility in Research Triangle Park, North Carolina intended to support a broad range of clinical programs. The initial estimate of the minimum amount of undiscounted lease payments due under this lease is ~~$81.1~~$69.0 million. The

tabular disclosure of minimum lease payments above under Note 7, Leases, does not include payments due under this lease. We anticipate that the facility will be operational in the first quarter of 2023. The project ~~will be~~is facilitated, in part, by a Job Development Investment Grant approved by the North Carolina Economic Investment Committee, which authorizes potential reimbursements based on new tax revenues generated through the project. The facility ~~will be~~is designed to support manufacturing for our ex vivocell therapy programs in hematology and oncology and in vivo non-viral delivery programs for liver diseases, with flexibility to support manufacturing of our viral delivery programs, and ultimately, scale-up to support potential commercial supply.

For our initial waves of clinical ~~programs,~~trials, we ~~will~~expect to use ~~contract manufacturing organizations, or~~ CMOs with relevant manufacturing experience in genetic medicines.

We believe our collection of base editing, gene editing and delivery technologies has significant potential across a broad array of genetic diseases. To fully realize this potential, we have established and will continue to seek out innovative collaborations, licenses, and strategic alliances with pioneering companies and with leading academic and research institutions. Additionally, we have and will continue to pursue relationships that potentially allow us to accelerate our preclinical research and development efforts. These relationships will allow us to aggressively pursue our vision of maximizing the potential of base editing to provide life-long cures for patients suffering from serious diseases.

In December 2021, we entered into a research collaboration agreement with Pfizer Inc., or Pfizer, focused on in vivo base editing programs for three targets for rare genetic diseases of the liver, muscle and central nervous system. The collaboration has an initial term of four years and may be extended for an additional one year on a program-by-program basis. Under the terms of the agreement, we will conduct all research activities through development candidate selection for three pre-specified, undisclosed targets, which are not included in our existing programs. Pfizer may opt in to exclusive, worldwide licenses to each development candidate, after which it will be responsible for all development activities, as well as potential regulatory approvals and commercialization, for each such development candidate. We have a right to opt in, at the end of Phase 1/2 clinical trials, upon the payment of an option exercise fee, to a global co-development and co-commercialization agreement with respect to one program licensed under the collaboration pursuant to which we and Pfizer would share net profits as well as development and commercialization costs in a 35%/65% ratio (Beam/Pfizer).

In June 2021, we entered into a research collaboration agreement with Apellis Pharmaceuticals, Inc., or Apellis, focused on the use of certain of our base editing technology to discover new treatments for complement system-driven diseases. Under the terms of the agreement, we will conduct preclinical research on up to six base editing programs that target specific genes within the complement system in various organs, including the eye, liver, and brain. Apellis has an exclusive option to license any or all of the six programs and will assume responsibility for subsequent development. We may elect to enter into a 50-50 U.S. co-development and co-commercialization agreement with Apellis with respect to one program licensed under the collaboration.

In April 2019, we entered into a collaboration and license agreement, or the Verve Agreement, with Verve Therapeutics, Inc., or Verve, a company focused on gene editing for cardiovascular disease treatments. This collaboration allows us to more fully realize the potential of base editing in treating cardiovascular disease, a disease area outside of our core focus and where Verve has significant expertise. Under the terms of the Verve Agreement, Verve received exclusive worldwide licenses to use our base editing technology and certain gene editing and delivery technologies for human therapeutic applications against certain cardiovascular targets. In exchange, we received shares of Verve common stock. Additionally, we are eligible to receive milestone payments for certain clinical and regulatory events for licensed products, and we retain the option, after the completion of Phase 1 clinical trials, to participate in future development and commercialization, and share 50 percent of U.S. profits and losses, for any licensed product directed against these targets.

In January 2021, Verve announced it had selected VERVE-101 as its lead product to be developed initially for the treatment of heterozygous familial hypercholesterolemia, or HeFH, a potentially fatal genetic heart disease. Individuals with HeFH have a genetic mutation causing high LDL-C levels in the blood. Over time, high LDL-C builds up in the heart’s arteries, resulting in reduced blood flow or blockage, and ultimately heart attack or stroke. Inactivation of the proprotein convertase subtilisin/kexin type 9, or PCSK9, gene has been shown to up-regulate LDL receptor expression, which leads to lower LDL-C levels. By making a single A-to-G change in the DNA genetic sequence of PCSK9, VERVE-101 aims to inactivate the target gene. In January 2021, Verve also reported preclinical proof-of-concept data in NHPs that demonstrated the successful use of ABEs to turn off PCSK9, and in January 2022, Verve announced it expects to submit an IND application for VERVE-101 in the second half of 2022.

Additionally, researchers at IOB have developed living models of the retina, known as organoids, which can be used to test novel therapies. Under the terms of the agreement with IOB, the parties will leverage IOB’s unique expertise in the field of ophthalmology along with our novel base editing technology to advance programs directed to the treatment of certain ocular diseases, including Stargardt disease.

In October 2021, we entered into an option and license agreement, or the Sana Agreement, with Sana Biotechnology, Inc., or Sana, pursuant to which we granted Sana non-exclusive research and development and commercial rights to our CRISPR Cas12b technology to perform nuclease editing for certain ex vivo engineered cell therapy programs. Under the terms of the Sana Agreement, licensed products include certain specified allogeneic T cell and stem cell-derived products directed at specified genetic targets, with certain limited rights for Sana to add and substitute such products and targets. The Sana Agreement excludes the grant of any Beam-controlled rights to perform base editing.

In July 2020, we entered into an alliance agreement, or the BCH Agreement, with Boston Children’s Hospital, or Boston Children’s. Under the terms of the BCH Agreement, we will identify and sponsor research programs to be performed at Boston Children’s, either solely by Boston Children’s or by both Boston Children’s and us, to facilitate the development of certain disease-specific therapies using our proprietary base editing technology. Boston Children’s will also serve as a clinical site to advance bench-to-bedside translation of our pipeline across certain therapeutic areas of interest, including programs in sickle cell disease and pediatric leukemias and exploration of new programs targeting other diseases.

In June 2020, we announced a non-exclusive research and clinical trial collaboration agreement with Magenta Therapeutics Inc., or Magenta, to evaluate the potential utility of MGTA-117, Magenta’s novel targeted antibody-drug conjugate, for conditioning of patients with sickle cell disease and beta-thalassemia receiving our base editing therapies. Conditioning is a critical component necessary to prepare a patient’s body to receive the edited cells, which carry the corrected gene and must engraft in the patient’s bone marrow in order to be effective. Today’s conditioning regimens rely on nonspecific chemotherapy or radiation, which are associated with significant toxicities. MGTA-117 is designed to precisely target only hematopoietic stem and progenitor cells, to spare immune cells, and has shown high selectivity, potent efficacy, wide safety margins and broad tolerability in NHP models. MGTA-117 may be capable of clearing space in bone marrow to support long-term engraftment and rapid recovery in patients. Combining the precision of our base editing technology with the more targeted conditioning regimen enabled by MGTA-117 has the potential to further improve therapeutic outcomes for patients suffering from these severe diseases.

In February 2021, we ~~entered into an Agreement and Plan of Merger, or the Guide Merger Agreement, to acquire~~acquired Guide Therapeutics, Inc., or ~~Guide. Pursuant to the~~ Guide, ~~Merger Agreement, we paid Guide’s former stockholders and optionholders~~for upfront consideration in an aggregate amount of $120.0 million, excluding customary purchase price adjustments, in shares of our common stock, based upon the volume-weighted average price of the common stock over the ten ~~trading day~~trading-day period ending on February 19, 2021. In addition, Guide’s former stockholders and optionholders are eligible to receive up to an additional $100.0 million in technology milestone payments and $220.0 million in product milestone payments, payable in our common stock.

With the ongoing concern related to the COVID-19 pandemic, ~~in the year ended December 31, 2020 and the nine months ended September 30, 2021,~~ we ~~have~~ maintained ~~and expanded~~ our business continuity plans to address and mitigate the impact of the COVID-19 pandemic on our business. In March 2020, to protect the health of our employees, and their families and communities, we restricted access to our offices to personnel who performed critical activities that must be completed on-site, limited the number of such personnel that can be present at our facilities at any one time, and requested that most of our employees work remotely. In May 2020, as certain states eased restrictions, we established new protocols to better allow our full laboratory staff access to our facilities. These protocols included several shifts working over a seven-day week protocol. In June 2021, as states continued to ease restrictions, we started to allow for all of our employees to work on-site at our facilities, with fewer restrictions, particularly for vaccinated employees. We expect to continue incurring additional costs to ensure we adhere to the guidelines instituted by the Centers for Disease Control and to provide a safe working environment to our onsite employees.

The extent to which the COVID-19 pandemic impacts our business, our corporate development objectives, results of operations and financial condition, including the value of and market for our common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the duration, scope and severity of the pandemic, the existence and duration ~~and extent~~ of any travel restrictions ~~and social distancing~~or business restrictions in the United States and other countries, business closures and business disruptions, the effectiveness of actions taken in the United States and other countries to contain and treat the disease,periodic spikes in infection rates, new strains of the virus that cause outbreaks of COVID-19, and the broad availability of effective ~~vaccines.~~vaccines and therapeutics.

Disruptions to the global economy and supply chain, disruption of global healthcare systems, and other significant impacts of the COVID-19 pandemic could have a material adverse effect on our business, financial condition, results of operations and growth prospects.

While the COVID-19 pandemic did not significantly impact our business or results of operations during the ~~nine~~three months ended ~~September 30, 2021,~~March 31, 2022, the length and extent of the pandemic, its consequences, and containment efforts will determine ~~the~~its future impact on our operations and financial condition.

Our management’s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which we have prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.

Our critical accounting policies are those policies which require the most significant judgments and estimates in the preparation of our condensed consolidated financial statements. We have determined that our most critical accounting policies are those relating to stock-based compensation, variable interest entities, fair value measurements, and leases. There have been no significant changes to our existing critical accounting policies and significant accounting policies discussed in the ~~2020~~2021 Form ~~10-K, except as discussed below.~~

~~In 2018, we adopted ASU 2017-01,~~ ~~Business Combinations~~, or ASU 2017-01, which clarified the definition of a business. We measure and recognize asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs, and the consideration is allocated to the items acquired based on a relative fair value methodology. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost allocated to acquire in-process research and development with no alternative future use is charged to research and development expense at the acquisition date.

~~At the time of acquisition, we determine if a transaction should be accounted for as a business combination or acquisition of assets.~~

We may be required to make milestone payments to the former stockholders and optionholders of Guide in the form of our common stock based on the achievement of certain product and technology milestones. The payments are accounted for under ASC 480, ~~Distinguishing Liabilities from Equity~~. These contingent consideration liabilities are carried at fair value which was estimated by applying a probability-based model, which utilized inputs primarily based upon the achievement and related timing of certain product and technology milestones that were unobservable in the market. The estimated fair value of contingent consideration liabilities, initially measured and recorded on the acquisition date, are considered to be a Level 3 measurement and are reviewed quarterly, or whenever events or circumstances occur that indicate a change in fair value. The contingent consideration liabilities are recorded at fair value at the end of each reporting period with changes in estimated fair values recorded in other income (expense) in the condensed consolidated statements of operations and other comprehensive loss.

The estimated fair value is determined based on probability adjusted discounted cash flow models that include significant estimates and assumptions pertaining to technology and product development. Significant changes in any of the probabilities of success would result in a significantly higher or lower fair value measurement. Significant changes in the probabilities as to the periods in which milestones will be achieved would result in a significantly lower or higher fair value measurement.10-K.

We were ~~incorporated on~~founded in January ~~25,~~ 2017 and ~~commenced~~began operations ~~shortly thereafter.~~in July 2017. Since our inception, we have devoted substantially all of our resources to building our base editing platform and advancing development of our portfolio of programs, establishing and protecting our intellectual property, conducting research and development activities, organizing and staffing our company, business planning, raising capital and providing general and administrative support for these operations. To date, we have financed our operations primarily through the sales of our redeemable convertible preferred stock, proceeds from offerings of our common stock and payments received under collaboration and license agreements.

We are ~~a development stage~~an early-stage company, and all of our programs are at a preclinical or early clinical stage of development. To date, we have not generated any revenue from product sales and do not expect to generate revenue from the sale of ~~our~~ products for the foreseeable future.Our revenue to date has been primarily derived from license and collaboration agreements with partners. Since inception we have incurred significant operating losses. Our net losses for the ~~nine~~three months ended ~~September 30,~~March 31, 2022 and 2021, ~~and 2020~~ were ~~$305.9~~$69.2 million, and ~~$99.1~~$201.6 million, respectively. As of ~~September 30, 2021,~~March 31, 2022, we had an accumulated deficit of ~~$703.6~~$837.5 million. We expect to continue to incur significant expenses and increasing operating losses in connection with ongoing development activities related to our ~~portfolio of~~internal programs and collaborations as we continue our preclinical and clinical development of product candidates; advance ~~these~~additional product candidates toward clinical development; build and operate our cGMP facility in North ~~Carolina,~~Carolina; further develop our base editing platform; continue to make investments in delivery technology for our base editors, including ~~in connection with~~the LNP technology we acquired through our acquisition of Guide; conduct research activities as we seek to discover and develop additional product candidates; maintain, expand, enforce, defend and protect our intellectual property portfolio; and continue to hire research and development, clinical, technical operations and commercial personnel. In addition, we expect to continue to incur ~~additional~~the costs associated with operating as a public company.

As a result of these anticipated expenditures, we will need to raise additional ~~financing~~capital to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our

operations through a combination of equity offerings, debt financings, collaborations, strategic alliances, and licensing arrangements. We may be unable to raise additional funds or enter into such other agreements when needed on favorable terms or at all. Our inability to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We can give no assurance that we will be able to secure such additional sources of ~~funds~~capital to support our operations, or, if such ~~funds are~~capital is available to us, that such additional ~~funding~~capital will be sufficient to meet our ~~needs.~~needs for the short or long term.

In April 2019, we entered into a collaboration and license agreement, or the Verve Agreement, with Verve Therapeutics, Inc., or Verve, a company focused on gene editing for cardiovascular disease treatments. In June 2021, we entered into a research collaboration agreement, or the Apellis Agreement, with Apellis Pharmaceuticals, Inc., or Apellis, focused on the use of certain of our base editing technology to discover new treatments for complement system-driven diseases. In October 2021, we entered into an option and license agreement, or the Sana Agreement, with Sana Biotechnology, Inc., or Sana, pursuant to which we granted Sana

non-exclusive research and development and commercial rights to our CRISPR Cas12b technology to perform nuclease editing for certain ex vivo engineered cell therapy programs. In December 2021, we entered into a research collaboration agreement, or the Pfizer Agreement, with Pfizer Inc., or Pfizer, focused on in vivo base editing programs for three targets for rare genetic diseases of the liver, muscle and central nervous system.

We have not generated any revenue to date from product sales and do not expect to do so in the near future. During the three months ended March 31, 2022 and 2021, we recognized $8.4 million and $6.0 thousand of revenue, respectively.

Research and development expenses consist of costs incurred in performing research and development activities, which include:

We expense research and development costs as incurred. Advance payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the benefits are consumed.

In the early phases of development, our research and development costs are often devoted to product platform and proof-of-concept preclinical studies that are not necessarily allocable to a specific target.

We expect that our research and development expenses will increase substantially ~~in connection with~~as we advance our programs through their planned preclinical and ~~future~~ clinical ~~development activities.~~development.

General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in our executive, intellectual property, business development and administrative functions. General and administrative expenses also include legal fees relating to intellectual property and corporate matters, professional fees for accounting, auditing, tax and consulting services, insurance costs, travel, and direct and allocated facility related expenses and other operating costs.

We anticipate that our general and administrative expenses will increase in the future to support our increased research and development activities. We also expect to continue to incur ~~increased~~ costs associated with being a public company and ~~implementing~~maintaining controls over financial reporting, including costs of accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with ~~the requirements of the~~ Nasdaq ~~Global Select Market~~ and SEC requirements, director and officer insurance costs, and investor and public relations costs.

Comparison of the three months ended ~~September 30,~~March 31, 2022 and 2021 ~~and 2020~~

License and collaboration revenue was approximately ~~$0.8~~$8.4 million and $6.0 thousand for the three months ended ~~September 30,~~March 31, 2022 and 2021, ~~and 2020,~~ respectively. License and collaboration revenue represents revenue recorded under the Pfizer, Apellis, and Verve Agreements.

Research and development expenses were ~~$54.6~~$65.4 million and ~~$29.8~~$190.1 million for the three months ended ~~September 30,~~March 31, 2022 and 2021, ~~and 2020,~~ respectively. The ~~increase~~decrease of ~~$24.8~~$124.7 million was primarily due to the following:

Research and development expenses are expected to continue to increase as we ~~start to~~ initiate clinical trials for BEAM-101, continue ~~IND enabling~~IND-enabling studies for BEAM-102 and BEAM-201, begin IND-enabling studies for BEAM-301, continue our current research programs, initiate new research programs, continue the preclinical and clinical development of our product candidates and conduct any future preclinical studies and begin to enroll patients in and conduct clinical trials for any of our product candidates.

General and administrative expenses were ~~$15.8~~$19.2 million and ~~$7.5~~$10.3 million for the three months ended ~~September 30,~~March 31, 2022 and 2021, ~~and 2020,~~ respectively. The increase of ~~$8.3~~$9.0 million was primarily due to the following:

During the three months ended ~~September 30, 2021,~~March 31, 2022, we recorded ~~$35.8~~$13.6 million of other income related to the change in fair value of success payment liabilities ~~as compared to $2.7 million of other income for the three months ended September 30, 2020~~ due to ~~decreases~~a decrease in the price of our common stock for the three months ended ~~September 30,~~March 31, 2022. During the three months ended March 31, 2021, ~~and 2020.~~we recorded $1.9 million of other expense due to an increase in the price of our common stock for the three months ended March 31, 2021. A portion of the success payment obligations were paid in June 2021; the remaining success payment obligations are still outstanding as of ~~September 30, 2021~~March 31, 2022 and will continue to be revalued at each reporting period.

During the three months ended ~~September 30,~~March 31, 2022 and 2021, we recorded $7.7 million of other expense and $1.0 million of ~~$4.9 million~~other income, respectively, as a result of ~~a decrease~~changes in the value of our investment in Verve's common stock.

During the three months ended ~~September 30,~~March 31, 2022 and 2021, we recorded ~~$10.6~~$0.5 million of other income and $0.3 million of other expense, respectively, related to the change in fair value of the Guide technology and product contingent consideration ~~liabilities as~~liabilities. These changes are a result of an update in project timelines and the expected probability of achievement of the milestones.

~~The decrease in interest~~Interest and other income (expense), net was $0.6 million for the three months ended March 31, 2022 as compared to $21.0 thousand of expense for the three months ended March 31, 2021. The increase was primarily due to ~~a decrease~~increases in interest income driven by ~~decreased~~increased market ~~rates.~~

~~The following table summarizes our results of operations, together with the change in dollars (in thousands):~~

License and collaboration revenue was approximately $0.8 million and $18.0 thousand for the nine months ended September 30, 2021 and September 30, 2020, respectively. License and collaboration revenue represents revenue recorded under the Apellis and the Verve Agreements.

Research and development expenses were $290.3 million and $70.7 million for the nine months ended September 30, 2021 and 2020, respectively. The increase of $219.6 million was primarily due to the following:

Research and development expenses are expected to continue to increase as we start to initiate clinical trials for BEAM-101, continue IND-enabling studies for BEAM-102, continue our current research programs, initiate new research programs, continue the preclinical development of our product candidates and conduct any future preclinical studies and begin to enroll patients and conduct clinical trials for any of our product candidates.

General and administrative expenses were $39.5 million and $21.3 million for the nine months ended September 30, 2021 and 2020, respectively. The increase of $18.2 million was primarily due to the following:

During the nine months ended September 30, 2021, we recorded $8.4 million of other expense related to the change in fair value of success payment liabilities as compared to $8.7 million of other expense for the nine months ended September 30, 2020 due to increases in the price of our common stock for the nine months ended September 30, 2021 and 2020. A portion of the success payments was paid in shares in June 2021; the remaining success payment obligations are still outstanding as of September 30, 2021 and will continue to be revalued at each reporting period.

~~During the nine months ended September 30, 2021 and 2020, we recorded income of $22.0 million and $0.5 million as a result of increases in the value of our investment in Verve's common stock.~~

During the nine months ended September 30, 2021, we recorded $9.6 million of other income related to the change in fair value of the Guide technology and product contingent consideration liabilities as a result of an update in project timelines and the expected probability of achievement of the milestones.

~~The decrease in interest and other income (expense), net was primarily due to a decrease in interest income driven by decreased market rates.~~portfolio.

Since our inception in January 2017, we have not generated any revenue from product sales, have generated only limited license and collaboration revenue from ~~the Verve Agreement~~our license and ~~the Apellis Agreement,~~collaboration agreements, and have incurred significant operating losses and negative cash flows from our operations. We expect to incur significant expenses and operating losses for the foreseeable future as we advance the preclinical and ~~if successful,~~ the clinical development of our product candidates. ~~In February 2020,~~

To date, we ~~completed~~have funded our IPO in which we issued and sold 12,176,471 shares of our common stock, including 1,588,235 shares of common stock sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a public offering price of $17.00 per share. We received net proceeds from our IPO of $188.3 million, after deducting underwriting discounts and offering expenses payable by us. In October 2020, we issued and sold 5,750,000 shares of our common stock, including 750,000 shares pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $23.50 per share, for aggregate gross proceeds of $135.1 million. We received approximately $126.6 million in net proceeds after deducting applicable underwriting discounts and offering expenses.operations primarily through equity offerings. In January 2021, we issued and sold 2,795,700 shares of our common stock in a private placement at an offering price of $93.00 per share for aggregate gross proceeds of $260.0 million. We received $252.0 million in net proceeds after deducting offering expenses payable by us. To date, we have funded our operations primarily through equity offerings.

In April 2021, we filed a universal shelf registration statement on Form S-3 with the SEC, or the 2021 Shelf, to register for sale an indeterminate amount of our common stock, preferred stock, debt securities, warrants and/or units in one or more offerings, which became effective upon filing with the SEC (File No. 333-254946).

In April 2021, we entered into an at the market, or ATM, sales agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, pursuant to which we were entitled to offer and sell, from time to time at prevailing market prices, shares of our common stock having aggregate gross proceeds of up to $300.0 million. We agreed to pay Jefferies a commission of up to 3.0% of the aggregate gross sale proceeds of any shares sold by Jefferies under the Sales Agreement. ~~As of September 30,~~Between April and July 2021, we ~~have~~ sold 2,908,009 shares of our common stock under the Sales Agreement at an average price of $103.16 per share for aggregate gross proceeds of $300.0 million, before deducting commissions and offering expenses payable by us.

In July 2021, we and Jefferies entered into an amendment to the Sales Agreement to provide for an increase in the aggregate offering amount under the Sales Agreement, such that as of July 7, 2021, we may offer and sell shares of common stock having an aggregate offering price of an additional $500.0 million. As of ~~September 30, 2021,~~March 31, 2022, we have sold ~~1,765,833~~2,873,956 additional shares of our common stock under the amended Sales Agreement at an average price of ~~$107.88~~$92.71 per share for aggregate gross proceeds of ~~$190.5~~$266.5 million, before deducting commissions and offering expenses payable by ~~us, resulting~~us.

In December 2021, we entered into the Pfizer Agreement, which is focused on in vivo base editing programs for three targets for rare genetic diseases of the liver, muscle and central nervous system. Under the terms of the Pfizer Agreement, we will conduct all research activities through development candidate selection for three undisclosed targets, which are not included in our existing programs. Pursuant to the Pfizer Agreement, we received an ~~aggregate~~upfront payment of ~~$490.5~~$300.0 million in ~~gross proceeds received under the Sales Agreement as of September 30, 2021.~~January 2022.

As of ~~September 30, 2021,~~March 31, 2022, we had ~~$933.4 million~~$1.2 billion in cash, cash equivalents, and marketable securities.

We are required to make success payments to Harvard and Broad Institute based on increases in the per share fair market value of our Series A-1 Preferred Stock and Series A-2 Preferred Stock or, subsequent to our IPO, our common stock. The amounts due may be settled in cash or shares of our common stock, at our discretion. In May 2021, the first success payment measurements occurred and success payments to Harvard and Broad Institute were calculated to be $15.0 million and $15.0 million, respectively. We elected to make each payment in shares of our common stock and issued 174,825 shares to each of Harvard and Broad Institute to settle these liabilities in June 2021. We may additionally owe Harvard and Broad Institute success payments of up to an additional $90.0 million each.

We have not yet commercialized any of our product candidates, and we do not expect to generate revenue from the sale of our ~~products~~product candidates for the foreseeable future. We anticipate that we may need to raise additional capital in order to continue to fund our research and development, including our planned preclinical studies and clinical trials, building, maintaining and operating a commercial-scale cGMP manufacturing facility, and new product development, as well as to fund our general operations. As ~~and if~~ necessary, we will seek to raise ~~these~~ additional ~~funds~~capital through various potential sources, such as equity and debt financings or through corporate collaboration and license agreements. ~~Especially in light of the COVID-19 pandemic, we~~We can give no assurances that we will be able to secure such additional sources of ~~funds~~capital to support our operations, or, if such funds are available to us, that such additional financing will be sufficient to meet our needs. ~~For a more detailed discussion of risks related to COVID-19, please see Part I, Item 1A,~~ ~~Risk Factors—Risks related to our relationships with third parties, included in our 2020 Form 10-K.~~

Net cash provided by operating activities for the three months ended March 31, 2022 was $218.5 million, consisting primarily of the collection of collaboration receivables of $300.0 million related to the Pfizer Agreement and an increase in other long-term liabilities of $8.3 million, in addition to noncash items consisting primarily of stock-based compensation expense of $18.0 million, a decrease in the fair value of a non-controlling equity investment of $7.7 million, depreciation and amortization expense of $3.3 million and a change in operating lease ROU assets of $2.0 million. These sources of cash were partially offset by our net loss of $69.2 million, decreases in accrued expenses and other liabilities of $16.5 million, deferred revenue of $8.4 million, operating lease liabilities of $1.8 million and accounts payable of $1.3 million, and an increase in prepaid expenses and other current assets of $9.2 million, as well as noncash items including decreases in the fair value of derivative liabilities of $13.6 million and in the fair value of contingent consideration liabilities of $0.5 million as well as amortization of investment premiums of $0.4 million.

Net cash used in operating activities for the ~~nine~~three months ended ~~September 30,~~March 31, 2021 was ~~$68.1~~$38.6 million, consisting primarily of our net loss of ~~$305.9~~$201.6 million, a decrease in accounts payable of $1.3 million and noncash items including an increase in the fair value of a non-controlling equity investment of $22.0 million and a change in fair value of contingent consideration liabilities of $9.6 million. These uses of cash were offset in part by an increase in deferred revenue of $49.2 million, primarily related to the Apellis Agreement; an increase in operating lease liabilities of $15.2 million; an increase in accrued expenses and other liabilities of $2.8 million and a decrease in prepaid expenses and other current assets of $0.7 million and noncash items consisting primarily of in-process research and development expenses of $155.0 million, stock-based compensation expense of $28.1 million, change in fair value of derivative liabilities of $8.4 million, a change in operating lease ROU assets of $6.8 million and depreciation and amortization expense of $4.8 million.

~~Net cash used in operating activities for the nine months ended September 30, 2020 was $71.4 million, consisting primarily of our net loss of $99.1~~$4.5 million, an increase in prepaid expenses and other current assets of ~~$3.7~~$2.4 million, a decrease in accounts payable of $0.7 million and other non-cash items of $1.0 million; offset by a change in operating lease liabilities of ~~$3.2 million; offset by an increase in accrued expenses and other liabilities of $4.2~~$6.1 million, and noncash ~~charges~~expenses consisting primarily of in-process research and development expense of $155.0 million related to our acquisition of Guide, stock-based compensation expense of ~~$8.6~~$4.6 million, change

in operating lease ROU assets of $2.4 million, change in fair value of derivative liabilities of ~~$8.7 million, non-cash research and developmental license expense, net of $5.2~~$1.9 million, depreciation and amortization expense of ~~$3.5~~$1.4 million and change in ~~operating lease ROU assets~~contingent consideration liabilities of ~~$3.1~~$0.3 million.

For the ~~nine~~three months ended ~~September 30,~~March 31, 2022, cash used in investing activities was primarily the net purchases of marketable securities of $530.1 million, and purchases of property and equipment of $7.3 million.

For the three months ended March 31, 2021, cash used in investing activities was primarily the net purchases of marketable securities of ~~$183.8~~$268.8 million, and purchases of property and equipment of ~~$33.4~~$11.5 million. We also received $0.6 million in ~~net~~ cash from our acquisition of Guide, after the payment of acquisition costs.

For the nine months ended September 30, 2020, cash used in investing activities was primarily the net purchases of marketable securities of $9.7 million, and purchases of property and equipment of $8.2 million.

Net cash provided by financing activities for the ~~nine~~three months ended ~~September 30, 2021~~March 31, 2022 consisted primarily of proceeds from equity offerings of ~~$737.2~~$54.0 million, $1.4 million of proceeds from the issuance of common stock under benefit plans, and proceeds from the exercise of stock options of $0.8 million, offset in part by repayments of equipment financing liabilities of $0.6 million.

Net cash provided by financing activities for the three months ended March 31, 2021 consisted primarily of proceeds from our private placement offering of $260.0 million and proceeds from the exercise of stock options of ~~$7.7~~$1.8 million, offset in part by the payment of equity offering costs of ~~$8.7~~$8.0 million and repayments of equipment financing liabilities of ~~$1.6 million.~~

Net cash provided by financing activities for the nine months ended September 30, 2020 consisted primarily of proceeds from our IPO of $192.5 million, net of underwriting discounts, proceeds of $1.6 million from equipment financings, and proceeds from the exercise of stock options of $1.1 million, offset by the payment of equity offering costs of $1.7 million, and repayments of equipment financing liabilities of $1.2$0.5 million.

Our operating expenses are expected to increase substantially as we continue to advance our portfolio of programs.

We expect that our cash, cash equivalents and marketable securities at ~~September 30, 2021~~March 31, 2022 will enable us to fund our current and planned operating expenses and capital expenditures for at least the ~~next 12 months.~~twelve calendar months beginning March 31, 2022 and beyond such twelve-month period. We have based these estimates on assumptions that may prove to be imprecise, and we may exhaust our available capital resources sooner ~~than~~that we currently expect. Because of the numerous risks and uncertainties associated with the development our programs, we are unable to estimate the amounts of increased capital outlays and operating expenses associated with completing the research and development of our product candidates.

A change in the outcome of any of these or other variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. Further, our operating plans may change in the future, and we may need additional funds to meet operational needs and capital requirements associated with such operating plans.

Until such time, if ever, as we can generate substantial ~~revenues from the sale of our~~ product ~~candidates,~~revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, and licensing arrangements. We do not have any committed external source of ~~funds.~~capital. We have historically relied on equity issuances to fund our capital needs and will likely rely on equity issuances in the future. Debt financing, if available, may involve agreements that include ~~restrictive~~ covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. ~~In addition, debt financings would result in increased fixed payment obligations.~~

If we raise ~~funds~~capital through additional collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates, or we may have to grant licenses on terms that may not be favorable to us. If we are unable to raise additional ~~funds~~capital through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our product development or, if approved, future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. We can give

no assurance that we will be able to secure such additional sources of funds to support our operations, or, if such funds are available to us, that such additional funding will be sufficient to meet our needs.

We enter into contracts in the normal course of business with contract research organizations and other vendors to assist in the performance of our research and development activities and other services and products for operating purposes. These contracts generally provide for termination on notice, and therefore are cancelable contracts and not included in ~~the table~~our calculations of contractual obligations and commitments. During the ~~nine~~three months ended ~~September 30, 2021,~~March 31, 2022, there were no material changes to our contractual obligations and commitments described under Management’s Discussion and Analysis of Financial Condition and Results of Operations in the ~~2020~~2021 Form ~~10-K with the exception of the commitments as described below.~~10-K.

During the nine months ended September 30, 2021, we entered into the second phase of our April 2019 lease for office and laboratory space to be built. The minimum of undiscounted lease payments due under the second phase of this lease is $42.7 million.

In May 2021, the first success payment measurements under the Harvard License Agreement and Broad License Agreement occurred and success payments to Harvard and Broad Institute were calculated to be $15.0 million and $15.0 million, respectively. We elected to make each payment in shares of our common stock and issued 174,825 shares of our common stock to each of Harvard and Broad Institute to settle these liabilities in June 2021.

~~We did not have during the periods presented and we do not currently have any off-balance sheet arrangements, as defined under the applicable regulations of the SEC.~~

We are exposed to market risk related to changes in interest rates. As of ~~September 30, 2021,~~March 31, 2022, we had cash, cash equivalents, and marketable securities of ~~$933.4 million,~~$1.2 billion, which consisted of cash, money market funds, commercial paper, ~~and~~ corporate notes ~~U.S. Treasury securities~~ and ~~government securities.~~a corporate equity security. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our investments are in short-term marketable securities. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, we believe an immediate 10% change in interest rates would not have a material effect on the fair market value of our investment portfolio. We have the ability to hold our investments until maturity, and therefore, we would not expect our operating results or cash flows to be affected to any significant degree by the effect of a change in market interest rates on our investment portfolio.

We are not currently exposed to significant market risk related to changes in foreign currency exchange rates; however, we do contract with vendors that are located outside of the United States and may be subject to fluctuations in foreign currency ~~exchange~~ rates. We may enter into additional contracts with vendors located outside of the United States in the future, which may increase our foreign currency exchange risk.

Inflation generally affects us by increasing our cost of labor and research, manufacturing and development costs. We believe that inflation has not had a material effect on our financial statements included elsewhere in this Quarterly Report on Form 10-Q. However, our operations may be adversely affected by inflation in the future.

Our management, with the participation of our principal executive officer and our principal financial officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Based on the evaluation of our disclosure controls and procedures as of ~~September 30, 2021,~~March 31, 2022, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures as of such date are effective at the reasonable assurance level.

We continuously seek to improve the efficiency and effectiveness of our internal controls. This results in refinements to processes throughout our company. There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and

15d-15(f) under the Exchange Act) during the quarter ended ~~September 30, 2021~~March 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Investing in our common stock involves a high degree of risk. For a detailed discussion of the risks that affect our ~~business, please~~business. Please refer to the sections titled “Risk Factors Summary” and “Item 1A. Risk Factors” in the ~~2020~~2021 Form ~~10-K and “Item 1A. Risk Factors” in our Quarterly Report on Form 10-Q for the quarters ended March 31, 2021 and June 30, 2021.~~10-K. The COVID-19 pandemic may also have the effect of heightening many of the other risks described in the section titled “Item 1A. Risk Factors” in each of the ~~2020~~2021 Form 10-K and our quarterly reports, such as risks related to our need to raise additional funding, fluctuation of our quarterly financial results, and our ability to obtain regulatory approvals for our product candidates.

The risk factors set forth below represent new risk factors or those containing changes to the similarly titled risk factor included in “Item 1.A Risk Factors” of the ~~2020~~2021 Form 10-K.

If any of the product candidates we may develop, or the delivery modes we rely on to administer them, cause serious adverse events, undesirable side effects, or unexpected characteristics, such events, side effects or characteristics could delay or prevent regulatory approval of the product candidates, limit the commercial potential, or result in significant negative consequences following any potential marketing approval.

We have not evaluated any product candidates in human clinical trials. Moreover, there have been only a limited number of clinical trials involving the use of gene editing technologies and none involving base editing technology similar to our technology. It is impossible to predict when or if any product candidates we may develop will prove safe in humans. In the genetic medicine field, there have been several significant adverse events from gene therapy treatments in the past, including reported cases of leukemia, serious blood disorders and death. There can be no assurance that base editing technologies, or components of our product candidates or methods of delivery, will not cause undesirable side effects, as improper editing of a patient’s DNA and other effects could lead to lymphoma, leukemia, or other cancers, other serious conditions or syndromes or other aberrantly functioning cells.

A significant risk in any base editing product candidate is that “off-target” edits may occur, which could cause serious adverse events, undesirable side effects or unexpected characteristics. For example, Erwei Zuo et al. reported that cytosine base editors generated substantial off-target edits, that is, edits in unintended locations on the DNA, when tested in mouse embryos. Such unintended edits are referred to as “spurious deamination.” We cannot be certain that off-target editing will not occur in any of our planned or future clinical studies, and the lack of observed side effects in preclinical studies does not guarantee that such side effects will not occur in human clinical studies. We have developed assays that can detect off-target edits, even when such edits occur at very low frequencies. Using these assays, we have observed off-target edits in our base editing product candidates. As the sensitivity of these assays increases, it is possible that we will continue to detect more such off-target edits. While we do not believe that the off-target edits we have observed to date have had a material adverse impact on the safety or benefit of our product candidates, if, in the future, we detect off-target edits for a product candidate that negatively impact safety or efficacy, our ability to develop the product candidate as a therapeutic could be adversely affected. There is also the potential risk of delayed adverse events following exposure to base editing therapy due to the permanence of edits to DNA or due to other components of product candidates used to carry the genetic material. Further, because base editing makes a permanent change, the therapy cannot be withdrawn, even after a side effect is observed. In addition, Rees et al. and Grunewald et al. have reported that the deaminases we currently use in our C base editors and our A base editors for use in DNA base editing also cause unintended mutations in RNA for as long as the editor is present in the cell.

Although we and others have demonstrated the ability to engineer base editors to improve the specificity of their edits in a laboratory setting, we cannot be sure that our engineering efforts will be effective in any product candidates that we may develop. For example, we might not be able to engineer an editor to make the desired change or a by-stander edit could diminish the effectiveness of an edit that we make.

In certain rare DNA sequence contexts, where more than one edit occurs on a contiguous piece of DNA, the repair of two or more nicks may lead to a deletion. For example, in our BEAM-101 program, where we are simultaneously editing two positions in the promoters of the HBG2 and HBG1 genes, which share >99% sequence identity and are contiguous due to a gene duplication event, we observed a 5 kb deletion in HBG2 at single digit percentages in animal studies. We do not believe that such a deletion represents a safety or efficacy concern because healthy individuals, including those with hereditary persistence of fetal hemoglobin, with naturally-occurring deletions at this locus, including some as large as 13 kb, have been documented. However, if we were to observe deletions that have a negative effect on HbF upregulation or on other important cellular attributes, our ability to develop BEAM-101 as a therapeutic could be adversely affected.

In certain of our programs, we plan to use LNPs to deliver our base editors. LNPs have been shown to induce oxidative stress in the liver at certain doses, as well as initiate systemic inflammatory responses that can be fatal in some cases. While we aim to continue to optimize our LNPs, there can be no assurance that our LNPs will not have undesired effects. Our LNPs could contribute, in whole or in part, to one or more of the following: immune reactions; infusion reactions; complement reactions; opsonization reactions; antibody reactions including IgA, IgM, IgE or IgG or some combination thereof; or reactions to the PEG from some lipids or PEG otherwise associated with the LNP. Certain aspects of our investigational medicines may induce immune reactions from either the mRNA or the lipid as well as adverse reactions within liver pathways or degradation of the mRNA or the LNP, any of which could lead to significant adverse events in one or more of our future clinical trials. Many of these types of side effects have been seen for legacy LNPs. There may be uncertainty as to the underlying cause of any such adverse event, which would make it difficult to accurately predict side effects in future clinical trials and would result in significant delays in our programs.

Our viral vectors including AAV or lentiviruses, which are relatively new approaches used for disease treatment, also have known side effects, and for which additional risks could develop in the future. In past clinical trials that were conducted by others with non-AAV vectors, several significant side effects were caused by gene therapy treatments, including reported cases of leukemia and death. Other potential side effects could include an immunologic reaction and insertional oncogenesis, which is the process whereby the insertion of a functional gene near a gene that is important in cell growth or division results in uncontrolled cell division, which could potentially enhance the risk of malignant transformation. If the vectors we use demonstrate a similar side effect, or other adverse events, we may be required to halt or delay further clinical development of any potential product candidates. Furthermore, the FDA has stated that lentiviral vectors possess characteristics that may pose high risks of delayed adverse events. Such delayed adverse events may occur in other viral vectors, including AAV vectors, at a lower rate.

In addition to side effects and adverse events caused by our product candidates, the conditioning administration process or related procedures which may be used in our electroporation pipeline also can cause adverse side effects and adverse events. Additionally, we have and may continue to collaborate with third parties to develop alternative conditioning regimes. We cannot predict if alternative conditioning regimes will be compatible with our product candidates. If in the future we are unable to demonstrate that such adverse events were caused by the conditioning regimens used, or administration process or related procedure, the FDA, the European Commission, EMA or other regulatory authorities could order us to cease further development of, or deny or limit approval of, our product candidates for any or all target indications. Even if we are able to demonstrate that adverse events are not related to the drug product or the administration of such drug product, such occurrences could affect patient recruitment, the ability of enrolled patients to complete the clinical trial, or the commercial viability of any product candidates that obtain regulatory approval.

If any product candidates we develop are associated with serious adverse events, undesirable side effects, or unexpected characteristics, we may need to abandon their development or limit development to certain uses or subpopulations in which the serious adverse events, undesirable side effects or other characteristics are less prevalent, less severe, or more acceptable from a risk-benefit perspective, any of which would have a material adverse effect on our business, financial condition, results of operations, and prospects. Many product candidates that initially showed promise in early stage testing for treating cancer or other diseases have later been found to cause side effects that prevented further clinical development of the product candidates.

If in the future we are unable to demonstrate that any of the above adverse events were caused by factors other than our product candidate, the FDA, the EMA or other regulatory authorities could order us to cease further development of, or deny approval of, any product candidates we are able to develop for any or all targeted indications. Even if we are able to demonstrate that all future serious adverse events are not product-related, such occurrences could affect patient recruitment or the ability of enrolled patients to complete the trial. Moreover, if we elect, or are required, to delay, suspend or terminate any clinical trial of any product candidate we may develop, the commercial prospects of such product candidates may be harmed and our ability to generate product revenues from any of these product candidates may be delayed or eliminated. Any of these occurrences may harm our ability to identify and develop product candidates, and may harm our business, financial condition, result of operations, and prospects significantly.

Additionally, if we successfully develop a product candidate and it receives marketing approval, the FDA could require us to adopt a Risk Evaluation and Mitigation Strategy, or REMS, to ensure that the benefits of treatment with such product candidate outweighs the risks for each potential patient, which may include, among other things, a medication guide outlining the risks of the product for distribution to patients, a communication plan to health care practitioners, extensive patient monitoring, or distribution systems and processes that are highly controlled, restrictive, and more costly than what is typical for the industry. Furthermore, if we or others later identify undesirable side effects caused by any product candidate that we develop, several potentially significant negative consequences could result, including:

Any of these events could prevent us from achieving or maintaining market acceptance of any product candidates we may identify and develop and could have a material adverse effect on our business, financial condition, and results of operations.

Our owned patents and patent applications and in-licensed patents and patent applications and other intellectual property may be subject to priority disputes or to inventorship disputes and similar proceedings. If we or our licensors are unsuccessful in any of these proceedings, we may be required to obtain licenses from third parties, which may not be available on commercially reasonable terms or at all, or to cease the development, manufacture, and commercialization of one or more of the product candidates we may develop, which could have a material adverse impact on our business.

Although we have an option to exclusively license certain patents and patent applications directed to Cas9 and Cas12a from Editas, who in turn has licensed such patents from various academic institutions including ~~the~~ Broad Institute, we do not currently have a license to such patents and patent applications. Certain of the U.S. patents and one U.S. patent application to which we hold an option are co-owned by ~~the~~ Broad Institute and MIT, and in some cases co-owned by ~~the~~ Broad Institute, Massachusetts Institute of Technology, or MIT, and Harvard, which we refer to together as the Boston Licensing Parties, and were involved in U.S. interference No. 106,048 with one U.S. patent application co-owned by the University of California, the University of Vienna, and Emmanuelle Charpentier, which we refer to together as the University of California. On September 10, 2018, the Court of Appeals for the Federal Circuit, or the CAFC, affirmed the Patent Trial and Appeal Board of the USPTO’s, or PTAB’s, holding that there was no interference-in-fact. An interference is a proceeding within the USPTO to determine priority of invention of the subject matter of patent claims filed by different parties.

On June 24, 2019, the PTAB declared an interference (U.S. Interference No. 106,115) between 10ten U.S. patent applications ((U.S. Serial Nos. 15/947,680; 15/947,700; 15/947,718; 15/981,807; 15/981,808; 15/981,809; 16/136,159; 16/136,165; 16/136,168; and 16/136,175) that are co-owned by the University of California, and 13 U.S. patents and one U.S. patent application (U.S. Patent Nos. 8,697,359; 8,771,945; 8,795,965; 8,865,406; 8,871,445; 8,889,356; 8,895,308; 8,906,616; 8,932,814; 8,945,839; 8,993,233; 8,999,641; and 9,840,713, and U.S. Serial No. 14/704,551)) that are co-owned by the Boston Licensing Parties, which we have an option to under the Editas License Agreement. In the declared interference, the University of California has been designated as the junior party and the Boston Licensing Parties have been designated as the senior party.

As a result of the declaration of interference, an adversarial proceeding in the USPTO before the PTAB has been initiated, which is declared to ultimately determine priority, specifically and which party was first to invent the claimed subject matter. Following oral arguments on the parties’ motions in May 2020, the PTAB issued a decision in September 2020, which included, in part, denying the Boston Licensing Parties motion that the University of California should be estopped in the current proceeding by the PTAB’s decision in the prior interference proceeding between the parties (No. 106,048), finding that the Boston Licensing Parties remain the senior party in the proceeding, and holding that the interference will proceed to the second, priority phase. An interference is typically divided into two phases. The first phase is referred to as the motions or preliminary motions phase while the second is referred to as the priority phase. In the first phase, each party may raise issues including but not limited to those relating to the patentability of a party’s claims based on prior art, written description, and enablement. A party also may seek an earlier priority benefit or may challenge whether the declaration of interference was proper in the first place. Priority, or a determination of who first invented the commonly claimed invention, is determined in the second phase of an interference. ~~Although we cannot predict with any certainty how long the priority phase will actually take, it may take approximately a year or longer before a decision is made by the PTAB.~~

The 10ten University of California patent applications and the 13 U.S. patents and one U.S. patent application co-owned by the Boston Licensing Parties involved in U.S. Interference No. 106,115 generally relate to CRISPR/Cas9 systems or eukaryotic cells comprising CRISPR/Cas9 systems having fused or covalently linked RNA and the use thereof in eukaryotic cells. On February 28, 2022, the PTAB issued a decision that the Boston Licensing Parties have priority of invention over University of California with respect to a single RNA CRISPR-Cas9 system that functions in eukaryotic cells. This decision is being appealed.

There can be no assurance that the U.S. interference will be resolved in favor of the Boston Licensing ~~Parties.~~Parties on appeal. If the U.S. interference resolves in favor of University of California, or if the Boston Licensing Parties’ patents and patent application are narrowed, invalidated, or held unenforceable, we may lose the ability to license the optioned patents and patent application and our ability to commercialize our product candidates may be adversely affected if we cannot obtain a license to relevant third party patents that cover our product candidates. We may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be nonexclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. If we are unable to obtain a

necessary license to a third-party patent on commercially reasonable terms, we may be unable to commercialize our base editing platform technology or product candidates or such commercialization efforts may be significantly delayed, which could in turn significantly harm our business.

We or our licensors may be subject to similar interferences in the future with the same risks as described above. For example, on December 14, 2020, the PTAB declared an interference (U.S. Interference No. 106,126) between 14 U.S. patents and two U.S. patent applications (U.S. Patent Nos. 8,697,359; 8,771,945; 8,795,965; 8,865,406; 8,871,445; 8,889,356; 8,889,418; 8,895,308; 8,906,616; 8,932,814; 8,945,839; 8,993,233; 8,999,641; and 9,840,713, and U.S. Serial Nos. 14/704,551 and 15/330,876) that are co-owned by the Boston Licensing Parties, which we have an option to under the Editas License Agreement, and one U.S. patent application (U.S. Serial ~~Nos.~~No. 14/685,510) that is owned by Toolgen, Inc, or Toolgen. In the declared interference, the Boston Licensing Parties have

been designated as the junior party and Toolgen has been designated as the senior party. In March 2021, the PTAB issued an order on preliminary motions, granting, in part, and denying, in part, certain motions proposed by the Boston Licensing Parties and Toolgen. Although we cannot predict with any certainty how long the preliminary motions phase will actually take, it may take approximately a year or longer before a decision on the motions is made by the PTAB. The 14 U.S. patents and two U.S. patent applications co-owned by the Boston Licensing Parties involved in U.S. Interference No. 106,126 generally relate to CRISPR/Cas9 systems or eukaryotic cells comprising CRISPR/Cas9 systems having fused or covalently linked RNA and the use thereof in eukaryotic cells.

On June 21, 2021, the PTAB declared an interference (U.S. Interference No. 106,133) between the same 14 U.S. patents and two U.S. patent applications (U.S. Patent Nos. 8,697,359; 8,771,945; 8,795,965; 8,865,406; 8,871,445; 8,889,356; 8,889,418; 8,895,308; 8,906,616; 8,932,814; 8,945,839; 8,993,233; 8,999,641; and 9,840,713, and U.S. Serial Nos. 14/704,551 and 15/330,876, co-owned by the Boston Licensing Parties) as named in the interference with Toolgen, and one U.S. patent application (U.S. Serial ~~Nos.~~No. 15/456,204) that is owned by Sigma-Aldrich Co., LLC, or Sigma-Aldrich. In the declared interference, the Boston Licensing Parties have been designated as the junior party and Sigma-Aldrich has been designated as the senior party. In September 2021, the PTAB issued an order on preliminary motions, granting, deferring, dismissing, or denying, certain motions proposed by the Boston Licensing Parties and Sigma-Aldrich. Although we cannot predict with any certainty how long the preliminary motions phase will actually take, it may take approximately a year or longer before a decision on the motions is made by the PTAB.

We or our licensors may also be subject to claims that former employees, collaborators, or other third parties have an interest in our owned patents or patent applications or in-licensed patents or patent applications or other intellectual property as an inventor or co-inventor. If we are unable to obtain an exclusive license to any such third-party co-owners’ interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors. In addition, we may need the cooperation of any such co-owners to enforce any patents that issue from such patent applications against third parties, and such cooperation may not be provided to us.

If we or our licensors are unsuccessful in any interference proceedings or other priority, validity (including any patent oppositions), or inventorship disputes to which we or they are subject, we may lose valuable intellectual property rights through the loss of one or more of our owned, licensed, or optioned patents, or such patent claims may be narrowed, invalidated, or held unenforceable, or through loss of exclusive ownership of or the exclusive right to use our owned or in-licensed patents. In the event of loss of patent rights as a result of any of these disputes, we may be required to obtain and maintain licenses from third parties, including parties involved in any such interference proceedings or other priority or inventorship disputes. Such licenses may not be available on commercially reasonable terms or at all, or may be non-exclusive. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture, and commercialization of one or more of the product candidates we may develop. The loss of exclusivity or the narrowing of our patent claims could limit our ability to stop others from using or commercializing similar or identical technology and product candidates. Even if we or our licensors are successful in an interference proceeding or other similar priority or inventorship disputes, it could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could result in a material adverse effect on our business, financial condition, results of operations, or prospects.

~~Item 2. Unregistered Sales~~The intellectual property landscape around gene editing technology, including base editing and delivery technology, is highly dynamic, and third parties may initiate legal proceedings alleging that we are infringing, misappropriating, or otherwise violating their intellectual property rights, the outcome of ~~Equity Securities~~which would be uncertain and ~~Uses of Proceeds~~may prevent, delay or otherwise interfere with our product discovery and development efforts.

~~We did not sell any unregistered securities~~gene editing, especially in the ~~three months ended September 30, 2021.~~

~~In February 2020, we closed our IPO~~base editing technology, is still in ~~which we issued~~its infancy, and ~~sold 12,176,471 shares of our common stock, including 1,588,235 shares of common stock sold pursuant~~no such product candidates have reached the market. Due to the underwriters’ full exercise of their option to purchase additional shares, at a public offering price of $17.00 per share, for aggregate gross proceeds of $207.0 million. We received approximately $188.3 millionintense research and development that is taking place by several companies, including us and our competitors, in ~~net proceeds after deducting underwriting discounts~~this field and offering expenses payable by us. None of the underwriting discounts and commissions or offering expenses were paid directly or indirectly to any directors or officers of ours or their associates or to persons owning 10% or more of any class of equity securities or to any affiliates of ours. All of the shares issued and sold in the ~~IPO were registered under~~field of delivery technology, the ~~Securities Act pursuant~~intellectual property landscape is evolving and in flux, and it may remain uncertain for the coming years. There may be significant intellectual property related litigation and proceedings relating to ~~a Registration Statement on Form S-1 (File No. 333-233985), which was declared effective by~~our owned and in-licensed, and other third party, intellectual property and proprietary rights in the SEC on February 5, 2020, and a Registration Statement on Form S-1 MEF (File No. 333-236284) filed pursuant to Rule 462(b) of the Securities Act. The offering commenced on February 5, 2020 and did not terminate until the sale of all the shares offered.future.

Our commercial success depends upon our ability and the ability of our collaborators and licensors to develop, manufacture, market, and sell any product candidates that we may develop and use our proprietary technologies without infringing, misappropriating, or otherwise violating the intellectual property and proprietary rights of third parties. The biotechnology and pharmaceutical industries are characterized by extensive litigation regarding patents and other intellectual property rights as well as administrative proceedings for challenging patents, including interference, derivation, inter partes review, post grant review, and reexamination proceedings

before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. We may be subject to and may in the future become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our base editing platform technology, delivery platform technology and any product candidates we may develop, including interference proceedings, post-grant review, inter partes review, and derivation proceedings before the USPTO and similar proceedings in foreign jurisdictions such as oppositions before the EPO. Numerous U.S. and foreign issued patents and pending patent applications that are owned by third parties exist in the fields in which we are developing our product candidates and they may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit.

As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our base editing platform technology, delivery platform technology and product candidates may give rise to claims of infringement of the patent rights of others. Moreover, it is not always clear to industry participants, including us, which patents cover various types of therapies, products or their methods of use or manufacture. We are aware of certain third-party patents and patent applications that, if issued, may be construed to cover our base editing technology, delivery technology and product candidates. There may also be third-party patents of which we are currently unaware with claims to technologies, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents.

Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the ~~net offering proceeds through~~fields in which we are developing product candidates. Our product candidates make use of CRISPR-based technology, which is a field that is highly active for patent filings. The extensive patent filings related to CRISPR and Cas make it difficult for us to assess the full extent of relevant patents and pending applications that may cover our base editing platform technology and product candidates and their use or manufacture. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our base editing platform technology and product candidates. For example, we are aware of a patent portfolio that is co-owned by the University of California, University of Vienna and Emmanuelle Charpentier, or the University of California Portfolio, which contains multiple patents and pending applications directed to gene editing. The University of California portfolio includes, for example, U.S. Patent Nos. 10,266,850; 10,227,611; 10,000,772; 10,113,167; 10,301,651; 10,308,961; 10,337,029; 10,351,878; 10,407,697; 10,358,659; 10,358,658; 10,385,360; 10,400,253; 10,421,980; 10,415,061; 10,428,352; 10,443,076; 10,487,341; 10,513,712; 10,519,467; 10,526,619; 10,533,190; 10,550,407; 10,563,227; 10,570,419; 10,577,631; 10,597,680; 10,612,045; 10,626,419; 10,640,791; 10,669,560; 10,676,759; 10,752,920; 10,774,344; 10,793,878; 10,900,054; 10,982,230; 10,982,231; 10,988,780; 10,988,782; 11,001,863; 11,008,589; 11,008,590; 11,028,412; 11,186,849; 11,242,543; 11,274,318; 11,293,034, which are expected to expire around March 2033, excluding any additional term for patent term adjustment, or PTA, or patent term extension, or PTE, and any disclaimed term for terminal disclaimers. The University of California portfolio also includes numerous additional pending patent applications. If these patent applications issue as patents, they are expected to expire around March 2033, excluding any PTA, PTE, and any disclaimed term for terminal disclaimers. As discussed above, certain applications in the University of California Portfolio are currently subject to U.S. Interference No. 106,115 with certain U.S. patents and one U.S. patent application that are co-owned by the Boston Licensing Parties to which we have an option under the Editas License Agreement. Although we have an option to exclusively license certain patents and patent applications directed to Cas9 and Cas12a from Editas, who in turn has licensed such patents from various academic institutions including Broad Institute, we do not currently have a license to such patents and patent applications. Certain members of the University of California Portfolio are being opposed in Europe by multiple parties. For example, the EPO Opposition Division has initiated opposition proceedings against European Patent Nos. EP2,800,811 B1, and EP3,241,902 B1and EP3401400 B1, which are estimated to expire in March 2033 (excluding any patent term adjustments or extensions). The opposition procedure before the EPO allows one or more third parties to challenge the validity of a granted European patent within nine months after grant date of the European patent. Opposition proceedings may involve issues including, but not limited to, priority, patentability of the claims involved, and procedural formalities related to the filing of the patent application. As a result of the opposition proceedings, the Opposition Division can revoke a patent, maintain the patent as granted, or maintain the patent in an amended form. Most of the claims of European patent EP 2,800,811 B1 were maintained without amendment by the Opposition Division, but this ~~Quarterly Report~~decision is being appealed. In April 2021, the claims of European patent EP3,241,902 B1 were revoked in their entirety, and that decision is not being appealed. In February 2022, the claims of European patent EP3,401,400 B1 were maintained in amended form by the Opposition Division, and it is uncertain if this decision will be appealed. If these patents are maintained by the Opposition Division with claims similar to those that are currently opposed, our ability to commercialize our product candidates may be adversely affected if we do not obtain a license to these patents. We may not be able to obtain any required license on ~~Form 10-Q, is consistent with~~commercially reasonable terms or at all. Even if we were able to obtain a license, it could be nonexclusive, thereby giving our competitors and other third parties access to the ~~use~~same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, we may be unable to commercialize our base editing platform technology or product candidates or such commercialization efforts may be significantly delayed, which could in turn significantly harm our business.

Numerous other patents and patent applications have been filed by other third parties directed to gene editing, guide nucleic acids, PAM sequence variants, split inteins, Cas12b or gene editing in the context of ~~proceeds described~~immune therapy or chimeric antigen receptors.

Because of the large number of patents issued and patent applications filed in our ~~final prospectus filed with~~field, third parties may allege they have patent rights encompassing our product candidates, technologies or methods. Third parties may assert that we are employing their proprietary technology without authorization and may file patent infringement claims or lawsuit against us, and if we are found to infringe such third-party patents, we may be required to pay damages, cease commercialization of the ~~SEC pursuant~~infringing technology, or obtain a license from such third parties, which may not be available on commercially reasonable terms or at all.

Our ability to ~~Rule 424(b)(4)~~commercialize our product candidates in the United States and abroad may be adversely affected if we cannot obtain a license on ~~February 7, 2020, and~~commercially reasonable terms to relevant third-party patents that cover our product candidates, delivery platform technology or base editing platform technology. Even if we believe third-party intellectual property claims are without merit, there ~~has been~~is no ~~material change~~assurance that a court would find in our ~~planned use~~favor on questions of infringement, validity, enforceability, or priority. A court of competent jurisdiction could hold that these third-party patents are valid, enforceable, and infringed, which could materially and adversely affect our ability to commercialize any product candidates we may develop and any other product candidates or technologies covered by the asserted third-party patents. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. If we are found to infringe a third party’s intellectual property rights, and we are unsuccessful in demonstrating that such patents are invalid or unenforceable, we could be required to obtain a license from such third party to continue developing, manufacturing, and marketing any product candidates we may develop and our technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, we may be unable to commercialize our base editing platform technology, delivery platform technology or product candidates or such commercialization efforts may be significantly delayed, which could in turn significantly harm our business. We also could be forced, including by court order, to cease developing, manufacturing, and commercializing the infringing technology or product candidates. In addition, we could be found liable for significant monetary damages, including treble damages and attorneys’ fees, if we are found to have willfully infringed a patent or other intellectual property right. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar material adverse effect on our business, financial condition, results of operations, and prospects.

Defense of third-party claims of infringement of misappropriation, or violation of intellectual property rights involves substantial litigation expense and would be a substantial diversion of management and employee time and resources from our business. Some third parties may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect on our business, financial condition, results of operations and prospects. There could also be public announcements of the ~~balance~~results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Any of the ~~net proceeds from~~foregoing events could have a material adverse effect on our ~~IPO described in such prospectus.~~business, financial condition, results of operations and prospects.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


Delaware	81-5238376
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

~~26 Landsdowne~~238 Main Street Cambridge, MA	~~02139~~02142
(Address of principal executive offices)	(Zip Code)


Large accelerated filer	☐☒	Accelerated filer	☐

Non-accelerated filer	☒☐	Smaller reporting company	☐

		Emerging growth company	☒☐


		Page
PART I	Financial Information
Item 1.	Financial Statements (Unaudited)	1
	Condensed Consolidated Balance Sheets	1
	Condensed Consolidated Statements of Operations and Other Comprehensive Loss	2
	Condensed Consolidated Statements of ~~Redeemable Convertible Preferred Stock and~~ Stockholders’ Equity ~~(Deficit)~~	3
	Condensed Consolidated Statements of Cash Flows	5
	Notes to Condensed Consolidated Financial Statements	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2322
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	3735
Item 4.	Controls and Procedures	3736

PART II	Other Information
Item 1.	Legal Proceedings	3937
Item 1A.	Risk Factors	39
~~Item 2.~~	~~Unregistered Sales of Equity Security and Uses of Proceeds~~	4237
Item 6.	Exhibits	4341
Signatures		4442


	Number of options			Weighted average exercise price		Number of options			Weighted average exercise price
Outstanding at December 31, 2020		5,336,441		$	9.70
Outstanding at December 31, 2021							6,034,192		$	32.40
Granted		1,638,143			88.57		1,427,500			69.13
Exercised		(774,352	)		9.89		(176,652	)		4.64
Forfeitures		(60,982	)		28.53		(20,637	)		36.41
Outstanding at September 30, 2021		6,139,250			30.53
Exercisable as of September 30, 2021		2,008,588		$	9.57
Outstanding at March 31, 2022							7,264,403			40.28
Exercisable as of March 31, 2022							2,602,709		$	15.83


	Shares			Weighted- average grant date fair value
Unvested as of December 31, 2020		1,275,338		$	10.95
Issued		819,830			88.13
Vested		(799,609	)		4.61
Cancelled		(8,725	)		80.04
Unvested as of September 30, 2021		1,286,834		$	63.59


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO


	Nine Months Ended September 30, 2021
	Harvard			Broad Institute			Total
Balance at December 31, 2020	$	35,500		$	35,700		$	71,200
Payments		(15,000	)		(15,000	)		(30,000	)
Change in fair value		4,200			4,200			8,400
Balance at September 30, 2021	$	24,700		$	24,900		$	49,600


	Shares			Weighted- average grant date fair value
Unvested as of December 31, 2021		1,126,206		$	74.32
Issued		711,025			57.30
Vested		(283,186	)		38.69
Forfeited		(11,519	)		86.15
Unvested as of March 31, 2022		1,542,526		$	72.93


	As of September 30,
	2021		2020
Unvested restricted stock		1,286,834		1,492,203
Outstanding options to purchase common stock		6,139,250		5,633,485
Total		7,426,084		7,125,688


	As of March 31,
	2022		2021
Unvested restricted stock		1,542,526		1,388,114
Outstanding options to purchase common stock		7,264,403		6,108,126
Total		8,806,929		7,496,240


	BEAM THERAPEUTICS INC.

Date: ~~November 8, 2021~~May 9, 2022	By:	/s/ John Evans
		John Evans
		Chief Executive Officer
		(Principal executive officer)


Date: ~~November 8, 2021~~May 9, 2022	By:	/s/ Terry-Ann Burrell
		Terry-Ann Burrell
		Chief Financial Officer and Treasurer
		(Principal financial and accounting officer)